Methods for the fermentative production of four carbon alcohols is provided. Specifically, butanol, preferably isobutanol is produced by the fermentative growth of a recombinant bacterium expressing an isobutanol biosynthetic pathway.
|
1. A recombinant microbial host cell comprising heterologous DNA molecules encoding polypeptides that catalyze substrate to product conversions for each step below:
i) pyruvate to acetolactate;
ii) acetolactate to 2,3-dihydroxyisovalerate;
iii) 2,3-dihydroxyisovalerate to α-ketoisovalerate; and
iv) α-ketoisovalerate to isobutyraldehyde;
wherein said microbial host cell produces isobutanol; and wherein
a) the polypeptide that catalyzes a substrate to product conversion of pyruvate to acetolactate is acetolactate synthase having the EC number 2.2.1.6;
b) the polypeptide that catalyzes a substrate to product conversion of acetolactate to 2,3-dihydroxyisovalerate is acetohydroxy acid isomeroreductase having the EC number 1.1.1.86;
c) the polypeptide that catalyzes a substrate to product conversion of 2,3-dihydroxyisovalerate to α-ketoisovalerate is acetohydroxy acid dehydratase having the EC number 4.2.1.9;
d) the polypeptide that catalyzes a substrate to product conversion of α-ketoisovalerate to isobutyraldehyde is branched-chain α-keto acid decarboxylase having the EC number 4.1.1.72.
2. A host cell according to
3. A host cell according to
12. A host cell according to
14. A host cell according to
15. A host cell according to
16. A host cell according to
18. A method for the production of isobutanol comprising:
1) providing a recombinant microbial host cell of
2) contacting the host cell of (i) with a fermentable carbon substrate in a fermentation medium under conditions whereby isobutanol is produced.
19. A method according to
20. A method according to
21. A method according to any of
22. A method according to any of
23. A method according to
24. A method according to
33. A method according to
35. An isobutanol containing fermentation medium produced by the method of
36. The host cell of
37. A host cell according to
|
This application claims priority under 35 U.S.C. §119 from U.S. Provisional Application Ser. No. 60/730,290, filed Oct. 26, 2005.
The invention relates to the field of industrial microbiology and the production of alcohols. More specifically, isobutanol is produced via industrial fermentation of a recombinant microorganism.
Butanol is an important industrial chemical, useful as a fuel additive, as a feedstock chemical in the plastics industry, and as a foodgrade extractant in the food and flavor industry. Each year 10 to 12 billion pounds of butanol are produced by petrochemical means and the need for this commodity chemical will likely increase.
Methods for the chemical synthesis of isobutanol are known, such as oxo synthesis, catalytic hydrogenation of carbon monoxide (Ullmann's Encyclopedia of Industrial Chemistry, 6th edition, 2003, Wiley-VCHVerlag GmbH and Co., Weinheim, Germany, Vol. 5, pp. 716-719) and Guerbet condensation of methanol with n-propanol (Carlini et al., J. Mol. Catal. A: Chem. 220:215-220 (2004)). These processes use starting materials derived from petrochemicals and are generally expensive and are not environmentally friendly. The production of isobutanol from plant-derived raw materials would minimize green house gas emissions and would represent an advance in the art.
Isobutanol is produced biologically as a by-product of yeast fermentation. It is a component of “fusel oil” that forms as a result of incomplete metabolism of amino acids by this group of fungi. Isobutanol is specifically produced from catabolism of L-valine. After the amine group of L-valine is harvested as a nitrogen source, the resulting α-keto acid is decarboxylated and reduced to isobutanol by enzymes of the so-called Ehrlich pathway (Dickinson et al., J. Biol. Chem. 273(40):25752-25756 (1998)). Yields of fusel oil and/or its components achieved during beverage fermentation are typically low. For example, the concentration of isobutanol produced in beer fermentation is reported to be less than 16 parts per million (Garcia et al., Process Biochemistry 29:303-309 (1994)). Addition of exogenous L-valine to the fermentation increases the yield of isobutanol, as described by Dickinson et al., supra, wherein it is reported that a yield of isobutanol of 3 g/L is obtained by providing L-valine at a concentration of 20 g/L in the fermentation. However, the use of valine as a feed-stock would be cost prohibitive for industrial scale isobutanol production. The biosynthesis of isobutanol directly from sugars would be economically viable and would represent an advance in the art. There have been no reports of a recombinant microorganism designed to produce isobutanol.
There is a need, therefore, for an environmentally responsible, cost-effective process for the production of isobutanol as a single product. The present invention addresses this need by providing a recombinant microbial production host that expresses an isobutanol biosynthetic pathway.
The invention provides a recombinant microorganism having an engineered isobutanol biosynthetic pathway. The engineered microorganism may be used for the commercial production of isobutanol. Accordingly, in one embodiment the invention provides a recombinant microbial host cell comprising at least one DNA molecule encoding a polypeptide that catalyzes a substrate to product conversion selected from the group consisting of:
i) pyruvate to acetolactate (pathway step a)
ii) acetolactate to 2,3-dihydroxyisovalerate (pathway step b)
iii) 2,3-dihydroxyisovalerate to α-ketoisovalerate (pathway step c)
iv) α-ketoisovalerate to isobutyraldehyde, (pathway step d), and
v) isobutyraldehyde to isobutanol; (pathway step e)
wherein the at least one DNA molecule is heterologous to said microbial host cell and wherein said microbial host cell produces isobutanol.
In another embodiment, the invention provides a recombinant microbial host cell comprising at least one DNA molecule encoding a polypeptide that catalyzes a substrate to product conversion selected from the group consisting of:
i) pyruvate to acetolactate, (pathway step a)
ii) acetolactate to 2,3-dihydroxyisovalerate, (pathway step b)
iii) 2,3-dihydroxyisovalerate to α-ketoisovalerate, (pathway step c)
iv) α-ketoisovalerate to isobutyryl-CoA, (pathway step f)
v) isobutyryl-CoA to isobutyraldehyde, (pathway step g), and
vi) isobutyraldehyde to isobutanol; (pathway step e)
wherein the at least one DNA molecule is heterologous to said microbial host cell and wherein said microbial host cell produces isobutanol.
In another embodiment, the invention provides a recombinant microbial host cell comprising at least one DNA molecule encoding a polypeptide that catalyzes a substrate to product conversion selected from the group consisting of:
i) pyruvate to acetolactate, (pathway step a)
ii) acetolactate to 2,3-dihydroxyisovalerate, (pathway step b)
iii) 2,3-dihydroxyisovalerate to α-ketoisovalerate, (pathway step c)
iv) α-ketoisovalerate to valine, (pathway step h)
v) valine to isobutylamine, (pathway step i)
vi) isobutylamine to isobutyraldehyde, (pathway step j), and
vii) isobutyraldehyde to isobutanol: (pathway step e)
wherein the at least one DNA molecule is heterologous to said microbial host cell and wherein said microbial host cell produces isobutanol.
In another embodiment, the invention provides a method for the production of isobutanol comprising:
i) pyruvate to acetolactate (pathway step a)
ii) acetolactate to 2,3-dihydroxyisovalerate (pathway step b)
iii) 2,3-dihydroxyisovalerate to α-ketoisovalerate (pathway step c)
iv) α-ketoisovalerate to isobutyraldehyde, (pathway step d), and
v) isobutyraldehyde to isobutanol; (pathway step e)
wherein the at least one DNA molecule is heterologous to said microbial host cell; and
In another embodiment, the invention provides a method for the production of isobutanol comprising:
i) pyruvate to acetolactate, (pathway step a)
ii) acetolactate to 2,3-dihydroxyisovalerate, (pathway step b)
iii) 2,3-dihydroxyisovalerate to α-ketoisovalerate, (pathway step c)
iv) α-ketoisovalerate to isobutyryl-CoA, (pathway step f)
v) isobutyryl-CoA to isobutyraldehyde, (pathway step g), and
vi) isobutyraldehyde to isobutanol; (pathway step e)
wherein the at least one DNA molecule is heterologous to said microbial host cell; and
In another embodiment, the invention provides a method for the production of isobutanol comprising:
i) pyruvate to acetolactate, (pathway step a)
ii) acetolactate to 2,3-dihydroxyisovalerate, (pathway step b)
iii) 2,3-dihydroxyisovalerate to α-ketoisovalerate, (pathway step c)
iv) α-ketoisovalerate to valine, (pathway step h)
v) valine to isobutylamine, (pathway step i)
vi) isobutylamine to isobutyraldehyde, (pathway step j), and
vii) isobutyraldehyde to isobutanol: (pathway step e)
wherein the at least one DNA molecule is heterologous to said microbial host cell; and
In an alternate embodiment the invention provides an isobutanol constraining fermentation medium produced by the methods of the invention.
The invention can be more fully understood from the following detailed description, FIGURE, and the accompanying sequence descriptions, which form a part of this application.
The following sequences conform with 37 C.F.R. 1.821-1.825 (“Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures—the Sequence Rules”) and are consistent with World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.
A Sequence Listing is provided herewith on Compact Disk. The contents of the Compact Disk containing the Sequence Listing are hereby incorporated by reference in compliance with 37 CFR 1.52(e). The Compact Disks are submitted in triplicate and are identical to one another. The disks are labeled “Copy 1—Sequence Listing”, “Copy 2—Sequence Listing”, and CRF. The disks contain the following file: CL3243 Seq List Conv.ST25 having the following size: 368,000 bytes and which was created Oct. 23, 2006.
TABLE 1
Summary of Gene and Protein SEQ ID Numbers
SEQ ID
NO:
SEQ ID
Nucleic
NO:
Description
acid
Peptide
Klebsiella pneumoniae budB
1
2
(acetolactate synthase)
Bacillus subtilis alsS
78
178
(acetolactate synthase)
Lactococcus lactis als
179
180
(acetolactate synthase)
E. coli ilvC (acetohydroxy acid
3
4
reductoisomerase)
S. cerevisiae ILV5
80
181
(acetohydroxy acid
reductoisomerase)
M. maripaludis ilvC
182
183
(Ketol-acid reductoisomerase)
B. subtilis ilvC
184
185
(acetohydroxy acid
reductoisomerase)
E. coli ilvD (acetohydroxy acid
5
6
dehydratase)
S. cerevisiae ILV3
83
186
(Dihydroxyacid dehydratase)
M. maripaludis ilvD
187
188
(Dihydroxy-acid dehydratase)
B. subtilis ilvD
189
190
(dihydroxy-acid dehydratase)
Lactococcus lactis kivD (branched-
7
8
chain α-keto acid decarboxylase),
codon optimized
Lactococcus lactis kivD (branched-
191
8
chain α-keto acid decarboxylase),
Lactococcus lactis kdcA
192
193
(branched-chain alpha-ketoacid
decarboxylase)
Salmonella typhimurium
194
195
(indolepyruvate decarboxylase)
Clostridium acetobutylicum pdc
196
197
(Pyruvate decarboxylase)
E. coli yqhD (branched-chain alcohol
9
10
dehydrogenase)
S. cerevisiae YPR1
198
199
(2-methylbutyraldehyde reductase)
S. cerevisiae ADH6
200
201
(NADPH-dependent cinnamyl alcohol
dehydrogenase)
Clostridium acetobutylicum bdhA
202
203
(NADH-dependent butanol
dehydrogenase A)
Clostridium acetobutylicum bdhB
158
204
Butanol dehydrogenase
B. subtilis bkdAA
205
206
(branched-chain keto acid
dehydrogenase E1 subunit)
B. subtilis bkdAB
207
208
(branched-chain alpha-keto acid
dehydrogenase E1 subunit)
B. subtilis bkdB
209
210
(branched-chain alpha-keto acid
dehydrogenase E2 subunit)
B. subtilis lpdV
211
212
(branched-chain alpha-keto acid
dehydrogenase E3 subunit)
P. putida bkdA1
213
214
(keto acid dehydrogenase E1-alpha
subunit)
P. putida bkdA2
215
216
(keto acid dehydrogenase E1-beta
subunit)
P. putida bkdB
217
218
(transacylase E2)
P. putida 1pdV
219
220
(lipoamide dehydrogenase)
C. beijerinckii ald
221
222
(coenzyme A acylating aldehyde
dehydrogenase)
C. acetobutylicum adhe1
223
224
(aldehyde dehydrogenase)
C. acetobutylicum adhe
225
226
(alcohol-aldehyde dehydrogenase)
P. putida nahO
227
228
(acetaldehyde dehydrogenase)
T. thermophilus
229
230
(acetaldehyde dehydrogenase)
E. coli avtA
231
232
(valine-pyruvate transaminase)
B. licheniformis avtA
233
234
(valine-pyruvate transaminase)
E. coli ilvE
235
236
(branched chain amino acid
aminotransferase)
S. cerevisiae BAT2
237
238
(branched chain amino acid
aminotransferase)
M. thermoautotrophicum
239
240
(branched chain amino acid
aminotransferase)
S. coelicolor
241
242
(valine dehydrogenase)
B.. subtilis bcd
243
244
(leucine dehydrogenase)
S. viridifaciens
245
246
(valine decarboxyase)
A. denitrificans aptA
247
248
(omega-amino acid:pyruvate
transaminase)
R. eutropha
249
250
(alanine-pyruvate transaminase)
S. oneidensis
251
252
(beta alanine-pyruvate transaminase)
P. putida
253
254
(beta alanine-pyruvate transaminase)
S. cinnamonensis icm
255
256
(isobutyrl-CoA mutase)
S. cinnamonensis icmB
257
258
(isobutyrl-CoA mutase)
S. coelicolor SCO5415
259
260
(isobutyrl-CoA mutase)
S. coelicolor SCO4800
261
262
(isobutyrl-CoA mutase)
S. avermitilis icmA
263
264
(isobutyrl-COA mutase)
S. avermitilis icmB
265
266
(isobutyrl-CoA mutase)
SEQ ID NOs:11-38, 40-69, 72-75, 85-138, 144, 145, 147-157, 159-176 are the nucleotide sequences of oligonucleotide cloning, screening or sequencing primers used in the Examples described herein.
SEQ ID NO:39 is the nucleotide sequence of the cscBKA gene cluster described in Example 16.
SEQ ID NO:70 is the nucleotide sequence of the glucose isomerase promoter 1.6GI described in Example 13.
SEQ ID NO:71 is the nucleotide sequence of the 1.5GI promoter described in Example 13.
SEQ ID NO:76 is the nucleotide sequence of the GPD promoter described in Example 17.
SEQ ID NO:77 is the nucleotide sequence of the CYC1 terminator described in Example 17.
SEQ ID NO:79 is the nucleotide sequence of the FBA promoter described in Example 17.
SEQ ID NO:81 is the nucleotide sequence of ADH1 promoter described in Example 17.
SEQ ID NO:82 is the nucleotide sequence of ADH1 terminator described in Example 17.
SEQ ID NO:84 is the nucleotide sequence of GPM promoter described in Example 17.
SEQ ID NO:139 is the amino acid sequence of sucrose hydrolase (CscA).
SEQ ID NO:140 is the amino acid sequence of D-fructokinase (CscK).
SEQ ID NO:141 is the amino acid sequence of sucrose permease (CscB).
SEQ ID NO:142 is the nucleotide sequence of plasmid pFP988DssPspac described in Example 20.
SEQ ID NO:143 is the nucleotide sequence of plasmid pFP988DssPgroE described in Example 20.
SEQ ID NO:146 is the nucleotide sequence of the pFP988Dss vector fragment described in Example 20.
SEQ ID NO:177 is the nucleotide sequence of the pFP988 integration vector described in Example 21.
SEQ ID NO:267 is the nucleotide sequence of plasmid pC194 described in Example 21.
The present invention relates to methods for the production of isobutanol using recombinant microorganisms. The present invention meets a number of commercial and industrial needs. Butanol is an important industrial commodity chemical with a variety of applications, where its potential as a fuel or fuel additive is particularly significant. Although only a four-carbon alcohol, butanol has an energy content similar to that of gasoline and can be blended with any fossil fuel. Butanol is favored as a fuel or fuel additive as it yields only CO2 and little or no SOx or NOx when burned in the standard internal combustion engine. Additionally butanol is less corrosive than ethanol, the most preferred fuel additive to date.
In addition to its utility as a biofuel or fuel additive, butanol has the potential of impacting hydrogen distribution problems in the emerging fuel cell industry. Fuel cells today are plagued by safety concerns associated with hydrogen transport and distribution. Butanol can be easily reformed for its hydrogen content and can be distributed through existing gas stations in the purity required for either fuel cells or vehicles.
Finally the present invention produces isobutanol from plant derived carbon sources, avoiding the negative environmental impact associated with standard petrochemical processes for butanol production.
The following definitions and abbreviations are to be used for the interpretation of the claims and the specification.
The term “invention” or “present invention” as used herein is a non-limiting term and is not intended to refer to any single embodiment of the particular invention but encompasses all possible embodiments as described in the specification and the claims.
The term “isobutanol biosynthetic pathway” refers to an enzyme pathways to produce isobutanol.
The terms “acetolactate synthase” and “acetolactate synthetase” are used interchangeably herein to refer to an enzyme that catalyzes the conversion of pyruvate to acetolactate and CO2. Preferred acetolactate synthases are known by the EC number 2.2.1.6 9 (Enzyme Nomenclature 1992, Academic Press, San Diego). These enzymes are available from a number of sources, including, but not limited to, Bacillus subtilis (GenBank Nos: CAB15618 (SEQ ID NO:178), Z99122 (SEQ ID NO:78), NCBI (National Center for Biotechnology Information) amino acid sequence, NCBI nucleotide sequence, respectively), Klebsiella pneumoniae (GenBank Nos: AAA25079 (SEQ ID NO:2), M73842 (SEQ ID NO:1)), and Lactococcus lactis (GenBank Nos: AAA25161 (SEQ ID NO:180), L16975 (SEQ ID NO:179)).
The terms “acetohydroxy acid isomeroreductase” and “acetohydroxy acid reductoisomerase” are used interchangeably herein to refer to an enzyme that catalyzes the conversion of acetolactate to 2,3-dihydroxyisovalerate using NADPH (reduced nicotinamide adenine dinucleotide phosphate) as an electron donor. Preferred acetohydroxy acid isomeroreductases are known by the EC number 1.1.1.86 and sequences are available from a vast array of microorganisms, including, but not limited to, Escherichia coli (GenBank Nos: NP—418222 (SEQ ID NO:4), NC—000913 (SEQ ID NO:3)), Saccharomyces cerevisiae (GenBank Nos: NP—013459 (SEQ ID NO:181), NC—001144 (SEQ ID NO:80)), Methanococcus maripaludis (GenBank Nos: CAF30210 (SEQ ID NO:183), BX957220 (SEQ ID NO:182)), and Bacillus. subtilis (GenBank Nos: CAB14789 (SEQ ID NO:185), Z99118 (SEQ ID NO:184)).
The term “acetohydroxy acid dehydratase” refers to an enzyme that catalyzes the conversion of 2,3-dihydroxyisovalerate to α-ketoisovalerate. Preferred acetohydroxy acid dehydratases are known by the EC number 4.2.1.9. These enzymes are available from a vast array of microorganisms, including, but not limited to, E. coli (GenBank Nos: YP—026248 (SEQ ID NO:6), NC—000913 (SEQ ID NO:5)), S. cerevisiae (GenBank Nos: NP—012550 (SEQ ID NO:186), NC 001142 (SEQ ID NO:83)), M. maripaludis (GenBank Nos: CAF29874 (SEQ ID NO:188), BX957219 (SEQ ID NO:187)), and B. subtilis (GenBank Nos: CAB14105 (SEQ ID NO:190), Z99115 (SEQ ID NO:189)).
The term “branched-chain α-keto acid decarboxylase” refers to an enzyme that catalyzes the conversion of α-ketoisovalerate to isobutyraldehyde and CO2. Preferred branched-chain α-keto acid decarboxylases are known by the EC number 4.1.1.72 and are available from a number of sources, including, but not limited to, Lactococcus lactis (GenBank Nos: AAS49166 (SEQ ID NO:193), AY548760 (SEQ ID NO:192); CAG34226 (SEQ ID NO:8), AJ746364 (SEQ ID NO:191), Salmonella typhimurium (GenBank Nos: NP—461346 (SEQ ID NO:195), NC—003197 (SEQ ID NO:194)), and Clostridium acetobutylicum (GenBank Nos: NP—149189 (SEQ ID NO:197), NC—001988 (SEQ ID NO:196)).
The term “branched-chain alcohol dehydrogenase” refers to an enzyme that catalyzes the conversion of isobutyraldehyde to isobutanol. Preferred branched-chain alcohol dehydrogenases are known by the EC number 1.1.1.265, but may also be classified under other alcohol dehydrogenases (specifically, EC 1.1.1.1 or 1.1.1.2). These enzymes utilize NADH (reduced nicotinamide adenine dinucleotide) and/or NADPH as electron donor and are available from a number of sources, including, but not limited to, S. cerevisiae (GenBank Nos: NP—010656 (SEQ ID NO:199), NC—001136 (SEQ ID NO:198); NP—014051 (SEQ ID NO:201) NC—001145 (SEQ ID NO:200)), E. coli (GenBank Nos: NP—417484 (SEQ ID NO:10), NC—000913 (SEQ ID NO:9)), and C. acetobutylicum (GenBank Nos: NP—349892 (SEQ ID NO:203), NC—003030 (SEQ ID NO:202); NP—349891 (SEQ ID NO:204), NC—003030 (SEQ ID NO:158)).
The term “branched-chain keto acid dehydrogenase” refers to an enzyme that catalyzes the conversion of α-ketoisovalerate to isobutyryl-CoA (isobutyryl-coenzyme A), using NAD+ (nicotinamide adenine dinucleotide) as electron acceptor. Preferred branched-chain keto acid dehydrogenases are known by the EC number 1.2.4.4. These branched-chain keto acid dehydrogenases are comprised of four subunits and sequences from all subunits are available from a vast array of microorganisms, including, but not limited to, B. subtilis (GenBank Nos: CAB14336 (SEQ ID NO:206), Z99116 (SEQ ID NO:205); CAB14335 (SEQ ID NO:208), Z99116 (SEQ ID NO:207); CAB14334 (SEQ ID NO:210), Z99116 (SEQ ID NO:209); and CAB14337 (SEQ ID NO:212), Z99116 (SEQ ID NO:211)) and Pseudomonas putida (GenBank Nos: AAA65614 (SEQ ID NO:214), M57613 (SEQ ID NO:213); AAA65615 (SEQ ID NO:216), M57613 (SEQ ID NO:215); AAA65617 (SEQ ID NO:218), M57613 (SEQ ID NO:217); and AAA65618 (SEQ ID NO:220), M57613 (SEQ ID NO:219)).
The term “acylating aldehyde dehydrogenase” refers to an enzyme that catalyzes the conversion of isobutyryl-CoA to isobutyraldehyde, using either NADH or NADPH as electron donor. Preferred acylating aldehyde dehydrogenases are known by the EC numbers 1.2.1.10 and 1.2.1.57. These enzymes are available from multiple sources, including, but not limited to, Clostridium beijerinckii (GenBank Nos: AAD31841 (SEQ ID NO:222), AF157306 (SEQ ID NO:221)), C. acetobutylicum (GenBank Nos: NP—149325 (SEQ ID NO:224), NC—001988 (SEQ ID NO:223); NP—149199 (SEQ ID NO:226), NC—001988 (SEQ ID NO:225)), P. putida (GenBank Nos: AAA89106 (SEQ ID NO:228), U13232 (SEQ ID NO:227)), and Thermus thermophilus (GenBank Nos: YP—145486 (SEQ ID NO:230), NC—006461 (SEQ ID NO:229)).
The term “transaminase” refers to an enzyme that catalyzes the conversion of α-ketoisovalerate to L-valine, using either alanine or glutamate as amine donor. Preferred transaminases are known by the EC numbers 2.6.1.42 and 2.6.1.66. These enzymes are available from a number of sources. Examples of sources for alanine-dependent enzymes include, but are not limited to, E. coli (GenBank Nos: YP—026231 (SEQ ID NO:232), NC—000913 (SEQ ID NO:231)) and Bacillus licheniformis (GenBank Nos: YP—093743 (SEQ ID NO:234), NC—006322 (SEQ ID NO:233)). Examples of sources for glutamate-dependent enzymes include, but are not limited to, E. coli (GenBank Nos: YP—026247 (SEQ ID NO:236), NC—000913 (SEQ ID NO:235)), S. cerevisiae (GenBank Nos: NP—012682 (SEQ ID NO:238), NC—001142 (SEQ ID NO:237)) and Methanobacterium thermoautotrophicum (GenBank Nos: NP—276546 (SEQ ID NO:240), NC—000916 (SEQ ID NO:239)).
The term “valine dehydrogenase” refers to an enzyme that catalyzes the conversion of α-ketoisovalerate to L-valine, using NAD(P)H as electron donor and ammonia as amine donor. Preferred valine dehydrogenases are known by the EC numbers 1.4.1.8 and 1.4.1.9 and are available from a number of sources, including, but not limited to, Streptomyces coelicolor (GenBank Nos: NP—628270 (SEQ ID NO:242), NC—003888 (SEQ ID NO:241)) and B. subtilis (GenBank Nos: CAB14339 (SEQ ID NO:244), Z99116 (SEQ ID NO:243)).
The term “valine decarboxylase” refers to an enzyme that catalyzes the conversion of L-valine to isobutylamine and CO2. Preferred valine decarboxylases are known by the EC number 4.1.1.14. These enzymes are found in Streptomycetes, such as for example, Streptomyces viridifaciens (GenBank Nos: AAN10242 (SEQ ID NO:246), AY116644 (SEQ ID NO:245)).
The term “omega transaminase” refers to an enzyme that catalyzes the conversion of isobutylamine to isobutyraldehyde using a suitable amino acid as amine donor. Preferred omega transaminases are known by the EC number 2.6.1.18 and are available from a number of sources, including, but not limited to, Alcaligenes denitrificans (AAP92672 (SEQ ID NO:248), AY330220 (SEQ ID NO:247)), Ralstonia eutropha (GenBank Nos: YP—294474 (SEQ ID NO:250), NC—007347 (SEQ ID NO:249)), Shewanella oneidensis (GenBank Nos: NP—719046 (SEQ ID NO:252), NC—004347 (SEQ ID NO:251)), and P. putida (GenBank Nos: AAN66223 (SEQ ID NO:254), AE016776 (SEQ ID NO:253)).
The term “isobutyryl-CoA mutase” refers to an enzyme that catalyzes the conversion of butyryl-CoA to isobutyryl-CoA. This enzyme uses coenzyme B12 as cofactor. Preferred isobutyryl-CoA mutases are known by the EC number 5.4.99.13. These enzymes are found in a number of Streptomycetes, including, but not limited to, Streptomyces cinnamonensis (GenBank Nos: AAC08713 (SEQ ID NO:256), U67612 (SEQ ID NO:255); CAB59633 (SEQ ID NO:258), AJ246005 (SEQ ID NO:257)), S. coelicolor (GenBank Nos: CAB70645 (SEQ ID NO:260), AL939123 (SEQ ID NO:259); CAB92663 (SEQ ID NO:262), AL939121 (SEQ ID NO:261)), and Streptomyces avermitilis (GenBank Nos: NP—824008 (SEQ ID NO:264), NC—003155 (SEQ ID NO:263); NP—824637 (SEQ ID NO:266), NC—003155 (SEQ ID NO:265)).
The term “a facultative anaerobe” refers to a microorganism that can grow in both aerobic and anaerobic environments.
The term “carbon substrate” or “fermentable carbon substrate” refers to a carbon source capable of being metabolized by host organisms of the present invention and particularly carbon sources selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and one-carbon substrates or mixtures thereof.
The term “gene” refers to a nucleic acid fragment that is capable of being expressed as a specific protein, optionally including regulatory sequences preceding (5′ non-coding sequences) and following (3′ non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign gene” or “heterologous gene” refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.
As used herein the term “coding sequence” refers to a DNA sequence that codes for a specific amino acid sequence. “Suitable regulatory sequences” refer to nucleotide sequences located upstream (5′ non-coding sequences), within, or downstream (3′ non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing site, effector binding site and stem-loop structure.
The term “promoter” refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3′ to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.
The term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of effecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.
The term “expression”, as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.
As used herein the term “transformation” refers to the transfer of a nucleic acid fragment into a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” or “recombinant” or “transformed” organisms.
The terms “plasmid”, “vector” and “cassette” refer to an extra chromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3′ untranslated sequence into a cell. “Transformation cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitates transformation of a particular host cell. “Expression cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.
As used herein the term “codon degeneracy” refers to the nature in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.
The term “codon-optimized” as it refers to genes or coding regions of nucleic acid molecules for transformation of various hosts, refers to the alteration of codons in the gene or coding regions of the nucleic acid molecules to reflect the typical codon usage of the host organism without altering the polypeptide encoded by the DNA.
Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) (hereinafter “Maniatis”); and by Silhavy, T. J., Bennan, M. L. and Enquist, L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1984); and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience (1987).
Isobutanol Biosynthetic Pathways
Carbohydrate utilizing microorganisms employ the Embden-Meyerhof-Parnas (EMP) pathway, the Entner-Doudoroff pathway and the pentose phosphate cycle as the central, metabolic routes to provide energy and cellular precursors for growth and maintenance. These pathways have in common the intermediate glyceraldehyde-3-phosphate and, ultimately, pyruvate is formed directly or in combination with the EMP pathway. Subsequently, pyruvate is transformed to acetyl-coenzyme A (acetyl-CoA) via a variety of means. Acetyl-CoA serves as a key intermediate, for example, in generating fatty acids, amino acids and secondary metabolites. The combined reactions of sugar conversion to pyruvate produce energy (e.g. adenosine-5′-triphosphate, ATP) and reducing equivalents (e.g. reduced nicotinamide adenine dinucleotide, NADH, and reduced nicotinamide adenine dinucleotide phosphate, NADPH). NADH and NADPH must be recycled to their oxidized forms (NAD+ and NADP+, respectively). In the presence of inorganic electron acceptors (e.g. O2, NO3− and SO42−), the reducing equivalents may be used to augment the energy pool; alternatively, a reduced carbon by-product may be formed.
The invention enables the production of isobutanol from carbohydrate sources with recombinant microorganisms by providing four complete reaction pathways, as shown in
This pathway combines enzymes known to be involved in well-characterized pathways for valine biosynthesis (pyruvate to α-ketoisovalerate) and valine catabolism (α-ketoisovalerate to isobutanol). Since many valine biosynthetic enzymes also catalyze analogous reactions in the isoleucine biosynthetic pathway, substrate specificity is a major consideration in selecting the gene sources. For this reason, the primary genes of interest for the acetolactate synthase enzyme are those from Bacillus (alsS) and Klebsiella (budB). These particular acetolactate synthases are known to participate in butanediol fermentation in these organisms and show increased affinity for pyruvate over ketobutyrate (Gollop et al., J. Bacteriol. 172(6):3444-3449 (1990); Holtzclaw et al., J. Bacteriol. 121(3):917-922 (1975)). The second and third pathway steps are catalyzed by acetohydroxy acid reductoisomerase and dehydratase, respectively. These enzymes have been characterized from a number of sources, such as for example, E. coli (Chunduru et al., Biochemistry 28(2):486-493 (1989); Flint et al., J. Biol. Chem. 268(29):14732-14742 (1993)). The final two steps of the preferred isobutanol pathway are known to occur in yeast, which can use valine as a nitrogen source and, in the process, secrete isobutanol. α-Ketoisovalerate can be converted to isobutyraldehyde by a number of keto acid decarboxylase enzymes, such as for example pyruvate decarboxylase. To prevent misdirection of pyruvate away from isobutanol production, a decarboxylase with decreased affinity for pyruvate is desired. So far, there are two such enzymes known in the art (Smit et al., Appl. Environ. Microbiol. 71(1):303-311 (2005); de la Plaza et al., FEMS Microbiol. Lett. 238(2):367-374 (2004)). Both enzymes are from strains of Lactococcus lactis and have a 50-200-fold preference for ketoisovalerate over pyruvate. Finally, a number of aldehyde reductases have been identified in yeast, many with overlapping substrate specificity. Those known to prefer branched-chain substrates over acetaldehyde include, but are not limited to, alcohol dehydrogenase VI (ADH6) and Ypr1p (Larroy et al., Biochem. J. 361 (Pt 1):163-172 (2002); Ford et al., Yeast 19(12):1087-1096 (2002)), both of which use NADPH as electron donor. An NADPH-dependent reductase, YqhD, active with branched-chain substrates has also been recently identified in E. coli (Sulzenbacher et al., J. Mol. Biol. 342(2):489-502 (2004)).
Another pathway for converting pyruvate to isobutanol comprises the following substrate to product conversions (
The first three steps in this pathway (a,b,c) are the same as those described above. The α-ketoisovalerate is converted to isobutyryl-CoA by the action of a branched-chain keto acid dehydrogenase. While yeast can only use valine as a nitrogen source, many other organisms (both eukaryotes and prokaryotes) can use valine as the carbon source as well. These organisms have branched-chain keto acid dehydrogenase (Sokatch et al. J. Bacteriol. 148(2):647-652 (1981)), which generates isobutyryl-CoA. Isobutyryl-CoA may be converted to isobutyraldehyde by an acylating aldehyde dehydrogenase. Dehydrogenases active with the branched-chain substrate have been described, but not cloned, in Leuconostoc and Propionibacterium (Kazahaya et al., J. Gen. Appl. Microbiol. 18:43-55 (1972); Hosoi et al., J. Ferment. Technol. 57:418-427 (1979)). However, it is also possible that acylating aldehyde dehydrogenases known to function with straight-chain acyl-CoAs (i.e. butyryl-CoA), may also work with isobutyryl-CoA. The isobutyraldehyde is then converted to isobutanol by a branched-chain alcohol dehydrogenase, as described above for the first pathway.
Another pathway for converting pyruvate to isobutanol comprises the following substrate to product conversions (
The first three steps in this pathway (a,b,c) are the same as those described above. This pathway requires the addition of a valine dehydrogenase or a suitable transaminase. Valine (and or leucine) dehydrogenase catalyzes reductive amination and uses ammonia; Km values for ammonia are in the millimolar range (Priestly et al., Biochem J. 261(3):853-861 (1989); Vancura et al., J. Gen. Microbiol. 134(12):3213-3219 (1988) Zink et al., Arch. Biochem. Biophys. 99:72-77 (1962); Sekimoto et al. J. Biochem (Japan) 116(1): 176-182 (1994)). Transaminases typically use either glutamate or alanine as amino donors and have been characterized from a number of organisms (Lee-Peng et al., J. Bacteriol. 139(2):339-345 (1979); Berg et al., J. Bacteriol. 155(3):1009-1014 (1983)). An alanine-specific enzyme may be desirable, since the generation of pyruvate from this step could be coupled to the consumption of pyruvate later in the pathway when the amine group is removed (see below). The next step is decarboxylation of valine, a reaction that occurs in valanimycin biosynthesis in Streptomyces (Garg et al., Mol. Microbiol. 46(2):505-517 (2002)). The resulting isobutylamine may be converted to isobutyraldehyde in a pyridoxal 5′-phosphate-dependent reaction by, for example, an enzyme of the omega-aminotransferase family. Such an enzyme from Vibrio fluvialis has demonstrated activity with isobutylamine (Shin et al., Biotechnol. Bioeng. 65(2):206-211 (1999)). Another omega-aminotransferase from Alcaligenes denitrificans has been cloned and has some activity with butylamine (Yun et al., Appl. Environ. Microbiol. 70(4):2529-2534 (2004)). In this direction, these enzymes use pyruvate as the amino acceptor, yielding alanine. As mentioned above, adverse affects on the pyruvate pool may be offset by using a pyruvate-producing transaminase earlier in the pathway. The isobutyraldehyde is then converted to isobutanol by a branched-chain alcohol dehydrogenase, as described above for the first pathway.
The fourth isobutanol biosynthetic pathway comprises the substrate to product conversions shown as steps k,g,e in
Thus, in providing multiple recombinant pathways from pyruvate to isobutanol, there exist a number of choices to fulfill the individual conversion steps, and the person of skill in the art will be able to utilize publicly available sequences to construct the relevant pathways. A listing of a representative number of genes known in the art and useful in the construction of isobutanol biosynthetic pathways are listed below in Table 2.
TABLE 2
Sources of Isobuatnol Biosynthetic Pathway Genes
Gene
GenBank Citation
acetolactate synthase
Z99122, Bacillus subtilis complete genome (section 19 of 21):
from 3608981 to 3809670
gi|32468830|emb|Z99122.2|BSUB0019[32468830]
M73842, Klebsiella pneumoniae acetolactate synthase (iluk) gene,
complete cds
gi|149210|gb|M73842.1|KPNILUK[149210]
L16975, Lactococcus lactis alpha-acetolactate synthase (als) gene,
complete cds
gi|473900|gb|L16975.1|LACALS[473900]
acetohydroxy acid
NC_000913, Escherichia coli K12, complete genome
isomeroreductase
gi|49175990|ref|NC_000913.2|[49175990]
NC_001144, Saccharomyces cerevisiae chromosome
XII, complete chromosome sequence
gi|42742286|ref|NC_001144.3|[42742286]
BX957220, Methanococcus maripaludis S2 complete
genome; segment 2/5
gi|44920669|emb|BX957220.1|[44920669]
Z99118, Bacillus subtilis complete genome (section 15
of 21): from 2812801 to 3013507
gi|32468802|emb|Z99118.2|BSUB0015[32468802]
acetohydroxy acid
NC_000913, Escherichia coli K12, complete genome
dehydratase
gi|49175990|ref|NC_000913.2|[49175990]
NC_001142, Saccharomyces cerevisiae chromosome
X, complete chromosome sequence
gi|42742252|ref|NC_001142.5|[42742252]
BX957219, Methanococcus maripaludis S2 complete
genome; segment 1/5
gi|45047123|emb|BX957219.1|[45047123]
Z99115, Bacillus subtilis complete genome (section 12
of 21): from 2207806 to 2409180
gi|32468778|emb|Z99115.2|BSUB0012|[32468778]
branched-chain α-keto
AY548760, Lactococcus lactis branched-chain alpha-
acid decarboxylase
ketoacid decarboxylase (kdcA) gene, complete cds
gi|44921616|gb|AY548760.1|[44921616]
AJ746364, Lactococcus lactis subsp. lactis kivd gene
for alpha-ketoisovalerate decarboxylase, strain IFPL730
gi|51870501|emb|AJ746364.1|[51870501]
NC_003197, Salmonella typhimurium LT2, complete genome
gi|16763390|ref|NC_003197.1|[16763390]
NC_001988, Clostridium acetobutylicum ATCC 824
plasmid pSOL1, complete sequence
gi|15004705|ref|NC_001988.2|[15004705]
branched-chain
NC_001136, Saccharomyces cerevisiae chromosome
alcohol
IV, complete chromosome sequence
dehydrogenase
gi|50593138|ref|NC_001136.6|[50593138]
NC_001145, Saccharomyces cerevisiae chromosome
XIII, complete chromosome sequence
gi|44829554|ref|NC_001145.2|[44829554]
NC_000913, Escherichia coli K12, complete genome
gi|49175990|ref|NC_000913.2|[49175990]
NC_003030, Clostridium acetobutylicum ATCC 824,
complete genome
gi|15893298|ref|NC_003030.1|[15893298]
branched-chain keto
Z99116, Bacillus subtilis complete genome (section 13
acid dehydrogenase
of 21): from 2409151 to 2613687
gi|32468787|emb|Z99116.2|BSUB0013[32468787]
M57613, Pseudomonas putida branched-chain keto
acid dehydrogenase operon (bkdA1, bkdA1 and bkdA2),
transacylase E2 (bkdB), bkdR and lipoamide
dehydrogenase (lpdV) genes, complete cds
gi|790512|gb|M57613.1|PSEBKDPPG2[790512]
acylating aldehyde
AF157306, Clostridium beijerinckii strain NRRL B593
dehydrogenase
hypothetical protein, coenzyme A acylating aldehyde
dehydrogenase (ald), acetoacetate:butyrate/acetate
coenzyme A transferase (ctfA),
acetoacetate:butyrate/acetate coenzyme A transferase
(ctfB), and acetoacetate decarboxylase (adc) genes,
complete cds
gi|47422980|gb|AF157306.2|[47422980]
NC_001988, Clostridium acetobutylicum ATCC 824
plasmid pSOL1, complete sequence
gi|15004705|ref|NC_001988.2|[15004705]
U13232, Pseudomonas putida NCIB9816 acetaldehyde
dehydrogenase (nahO) and 4-hydroxy-2-oxovalerate
aldolase (nahM) genes, complete cds, and 4-
oxalocrotonate decarboxylase (nahK) and 2-oxopent-4-
enoate hydratase (nahL) genes, partial cds
gi|595671|gb|U13232.1|PPU13232[595671]
transaminase
NC_000913, Escherichia coli K12, complete genome
gi|49175990|ref|NC_000913.2|[49175990]
NC_006322, Bacillus licheniformis ATCC 14580,
complete genome
gi|52783855|ref|NC_006322.1|[52783855]
NC_001142, Saccharomyces cerevisiae chromosome
X, complete chromosome sequence
gi|42742252|ref|NC_001142.5|[42742252]
NC_000916, Methanothermobacter thermautotrophicus
str. Delta H, complete genome
gi|15678031|ref|NC_000916.1|[15678031]
valine dehydrogenase
NC_003888, Streptomyces coelicolor A3(2), complete
genome
gi|32141095|ref|NC_003888.3|[32141095]
Z99116, Bacillus subtilis complete genome (section 13
of 21): from 2409151 to 2613687
gi|32468787|emb|Z99116.2|BSUB0013[32468787]
valine decarboxylase
AY116644,Streptomyces viridifaciens amino acid
aminotransferase gene, partial cds; ketol-acid
reductoisomerase, acetolactate synthetase small
subunit, acetolactate synthetase large subunit, complete
cds; azoxy antibiotic valanimycin gene cluster, complete
sequence; and putative transferase, and putative
secreted protein genes, complete cds
gi|27777548|gb|AY116644.1|[27777548]
omega transaminase
AY330220, Achromobacter denitrificans omega-amino
acid:pyruvate transaminase (aptA) gene, complete cds
gi|33086797|gb|AY330220.1|[33086797]
NC_007347, Ralstonia eutropha JMP134 chromosome
1, complete sequence
gi|73539706|ref|NC_007347.1|[73539706]
NC_004347, Shewanella oneidensis MR-1, complete
genome
gi|24371600|ref|NC_004347.1|[24371600]
NZ_AAAG02000002, Rhodospirillum rubrum Rrub02_2,
whole genome shotgun sequence
gi|48764549|ref|NZ_AAAG02000002.1|[48764549]
AE016776, Pseudomonas putida KT2440 section 3 of
21 of the complete genome
gi|26557019|gb|AE016776.1|[26557019]
isobutyryl-CoA mutase
U67612, Streptomyces cinnamonensis coenzyme B12-
dependent isobutyrylCoA mutase (icm) gene, complete
cds
gi|3002491|gb|U67612.1|SCU67612[3002491]
AJ246005, Streptomyces cinnamonensis icmB gene for
isobutyryl-CoA mutase, small subunit
gi|6137076|emb|AJ246005.1|SCI246005[6137076]
AL939123, Streptomyces coelicolor A3(2) complete
genome; segment 20/29
gi|24430032|emb|AL939123.1|SCO939123[24430032]
AL9939121, Streptomyces coelicolor A3(2) complete
genome; segment 18/29
gi|24429533|emb|AL939121.1|SCO939121[24429533]
NC_003155, Streptomyces avermitilis MA-4680,
complete genome
gi|57833846|ref|NC_003155.3|[57833846]
Microbial Hosts for Isobutanol Production
Microbial hosts for isobutanol production may be selected from bacteria, cyanobacteria, filamentous fungi and yeasts. The microbial host used for isobutanol production is preferably tolerant to isobutanol so that the yield is not limited by butanol toxicity. Microbes that are metabolically active at high titer levels of isobutanol are not well known in the art. Although butanol-tolerant mutants have been isolated from solventogenic Clostridia, little information is available concerning the butanol tolerance of other potentially useful bacterial strains. Most of the studies on the comparison of alcohol tolerance in bacteria suggest that butanol is more toxic than ethanol (de Cavalho et al., Microsc. Res. Tech. 64:215-22 (2004) and Kabelitz et al., FEMS Microbiol. Lett. 220:223-227 (2003)). Tomas et al. (J. Bacteriol. 186:2006-2018 (2004)) report that the yield of 1-butanol during fermentation in Clostridium acetobutylicum may be limited by 1-butanol toxicity. The primary effect of 1-butanol on Clostridium acetobutylicum is disruption of membrane functions (Hermann et al., Appl. Environ. Microbiol. 50:1238-1243 (1985)).
The microbial hosts selected for the production of isobutanol are preferably tolerant to isobutanol and should be able to convert carbohydrates to isobutanol. The criteria for selection of suitable microbial hosts include the following: intrinsic tolerance to isobutanol, high rate of glucose utilization, availability of genetic tools for gene manipulation, and the ability to generate stable chromosomal alterations.
Suitable host strains with a tolerance for isobutanol may be identified by screening based on the intrinsic tolerance of the strain. The intrinsic tolerance of microbes to isobutanol may be measured by determining the concentration of isobutanol that is responsible for 50% inhibition of the growth rate (IC50) when grown in a minimal medium. The IC50 values may be determined using methods known in the art. For example, the microbes of interest may be grown in the presence of various amounts of isobutanol and the growth rate monitored by measuring the optical density at 600 nanometers. The doubling time may be calculated from the logarithmic part of the growth curve and used as a measure of the growth rate. The concentration of isobutanol that produces 50% inhibition of growth may be determined from a graph of the percent inhibition of growth versus the isobutanol concentration. Preferably, the host strain should have an IC50 for isobutanol of greater than about 0.5%.
The microbial host for isobutanol production should also utilize glucose at a high rate. Most microbes are capable of utilizing carbohydrates. However, certain environmental microbes cannot utilize carbohydrates to high efficiency, and therefore would not be suitable hosts.
The ability to genetically modify the host is essential for the production of any recombinant microorganism. The mode of gene transfer technology may be by electroporation, conjugation, transduction or natural transformation. A broad range of host conjugative plasmids and drug resistance markers are available. The cloning vectors are tailored to the host organisms based on the nature of antibiotic resistance markers that can function in that host.
The microbial host also has to be manipulated in order to inactivate competing pathways for carbon flow by deleting various genes. This requires the availability of either transposons to direct inactivation or chromosomal integration vectors. Additionally, the production host should be amenable to chemical mutagenesis so that mutations to improve intrinsic isobutanol tolerance may be obtained.
Based on the criteria described above, suitable microbial hosts for the production of isobutanol include, but are not limited to, members of the genera Clostridium, Zymomonas, Escherichia, Salmonella, Rhodococcus, Pseudomonas, Bacillus, Lactobacillus, Enterococcus, Alcaligenes, Klebsiella, Paenibacillus, Arthrobacter, Corynebacterium, Brevibacterium, Pichia, Candida, Hansenula and Saccharomyces. Preferred hosts include: Escherichia coli, Alcaligenes eutrophus, Bacillus licheniformis, Paenibacillus macerans, Rhodococcus erythropolis, Pseudomonas putida, Lactobacillus plantarum, Enterococcus faecium, Enterococcus gallinarium, Enterococcus faecalis, Bacillus subtilis and Saccharomyces cerevisiae.
Construction of Production Host
Recombinant organisms containing the necessary genes that will encode the enzymatic pathway for the conversion of a fermentable carbon substrate to isobutanol may be constructed using techniques well known in the art. In the present invention, genes encoding the enzymes of one of the isobutanol biosynthetic pathways of the invention, for example, acetolactate synthase, acetohydroxy acid isomeroreductase, acetohydroxy acid dehydratase, branched-chain α-keto acid decarboxylase, and branched-chain alcohol dehydrogenase, may be isolated from various sources, as described above.
Methods of obtaining desired genes from a bacterial genome are common and well known in the art of molecular biology. For example, if the sequence of the gene is known, suitable genomic libraries may be created by restriction endonuclease digestion and may be screened with probes complementary to the desired gene sequence. Once the sequence is isolated, the DNA may be amplified using standard primer-directed amplification methods such as polymerase chain reaction (U.S. Pat. No. 4,683,202) to obtain amounts of DNA suitable for transformation using appropriate vectors. Tools for codon optimization for expression in a heterologous host are readily available. Some tools for codon optimization are available based on the GC content of the host organism. The GC content of some exemplary microbial hosts is given Table 3.
TABLE 3
GC Content of Microbial Hosts
Strain
% GC
B. licheniformis
46
B. subtilis
42
C. acetobutylicum
37
E. coli
50
P. putida
61
A. eutrophus
61
Paenibacillus macerans
51
Rhodococcus erythropolis
62
Brevibacillus
50
Paenibacillus polymyxa
50
Once the relevant pathway genes are identified and isolated they may be transformed into suitable expression hosts by means well known in the art. Vectors or cassettes useful for the transformation of a variety of host cells are common and commercially available from companies such as EPICENTRE® (Madison, Wis.), Invitrogen Corp. (Carlsbad, Calif.), Stratagene (La Jolla, Calif.), and New England Biolabs, Inc. (Beverly, Mass.). Typically the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5′ of the gene which harbors transcriptional initiation controls and a region 3′ of the DNA fragment which controls transcriptional termination. Both control regions may be derived from genes homologous to the transformed host cell, although it is to be understood that such control regions may also be derived from genes that are not native to the specific species chosen as a production host.
Initiation control regions or promoters, which are useful to drive expression of the relevant pathway coding regions in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genetic elements is suitable for the present invention including, but not limited to, CYC1, HIS3, GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI, CUP1, FBA, GPD, and GPM (useful for expression in Saccharomyces); AOX1 (useful for expression in Pichia); and lac, ara, tet, trp, IPL, IPR, T7, tac, and trc (useful for expression in Escherichia coli, Alcaligenes, and Pseudomonas); the amy, apr, npr promoters and various phage promoters useful for expression in Bacillus subtilis, Bacillus licheniformis, and Paenibacillus macerans; nisA (useful for expression Gram-positive bacteria, Eichenbaum et al. Appl. Environ. Microbiol. 64(8):2763-2769 (1998)); and the synthetic P11 promoter (useful for expression in Lactobacillus plantarum, Rud et al., Microbiology 152:1011-1019 (2006)).
Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary, however, it is most preferred if included.
Certain vectors are capable of replicating in a broad range of host bacteria and can be transferred by conjugation. The complete and annotated sequence of pRK404 and three related vectors-pRK437, pRK442, and pRK442(H) are available. These derivatives have proven to be valuable tools for genetic manipulation in Gram-negative bacteria (Scott et al., Plasmid 50(1):74-79 (2003)). Several plasmid derivatives of broad-host-range Inc P4 plasmid RSF1010 are also available with promoters that can function in a range of Gram-negative bacteria. Plasmid pAYC36 and pAYC37, have active promoters along with multiple cloning sites to allow for the heterologous gene expression in Gram-negative bacteria.
Chromosomal gene replacement tools are also widely available. For example, a thermosensitive variant of the broad-host-range replicon pWV101 has been modified to construct a plasmid pVE6002 which can be used to effect gene replacement in a range of Gram-positive bacteria (Maguin et al., J. Bacteriol. 174(17):5633-5638 (1992)). Additionally, in vitro transposomes are available to create random mutations in a variety of genomes from commercial sources such as EPICENTRE®.
The expression of an isobutanol biosynthetic pathway in various preferred microbial hosts is described in more detail below.
Expression of an Isobutanol Biosynthetic Pathway in E. coli
Vectors or cassettes useful for the transformation of E. coli are common and commercially available from the companies listed above. For example, the genes of an isobutanol biosynthetic pathway may be isolated from various sources, cloned into a modified pUC19 vector and transformed into E. coli NM522, as described in Examples 6 and 7.
Expression of an Isobutanol Biosynthetic Pathway in Rhodococcus erythropolis
A series of E. coli-Rhodococcus shuttle vectors are available for expression in R. erythropolis, including, but not limited to, pRhBR17 and pDA71 (Kostichka et al., Appl. Microbiol. Biotechnol. 62:61-68(2003)). Additionally, a series of promoters are available for heterologous gene expression in R. erythropolis (see for example Nakashima et al., Appl. Environ. Microbiol. 70:5557-5568 (2004), and Tao et al., Appl. Microbiol. Biotechnol. 2005, DOI 10.1007/s00253-005-0064). Targeted gene disruption of chromosomal genes in R. erythropolis may be created using the method described by Tao et al., supra, and Brans et al. (Appl. Environ. Microbiol. 66: 2029-2036 (2000)).
The heterologous genes required for the production of isobutanol, as described above, may be cloned initially in pDA71 or pRhBR71 and transformed into E. coli. The vectors may then be transformed into R. erythropolis by electroporation, as described by Kostichka et al., supra. The recombinants may be grown in synthetic medium containing glucose and the production of isobutanol can be followed using methods known in the art.
Expression of an Isobutanol Biosynthetic Pathway in b. Subtilis
Methods for gene expression and creation of mutations in B. subtilis are also well known in the art. For example, the genes of an isobutanol biosynthetic pathway may be isolated from various sources, cloned into a modified pUC19 vector and transformed into Bacillus subtilis BE1010, as described in Example 8. Additionally, the five genes of an isobutanol biosynthetic pathway can be split into two operons for expression, as described in Example 20. The three genes of the pathway (bubB, ilvD, and kivD) were integrated into the chromosome of Bacillus subtilis BE1010 (Payne and Jackson, J. Bacteriol. 173:2278-2282 (1991)). The remaining two genes (ilvC and bdhB) were cloned into an expression vector and transformed into the Bacillus strain carrying the integrated isobutanol genes
Expression of an Isobutanol Biosynthetic Pathway in B. licheniformis
Most of the plasmids and shuttle vectors that replicate in B. subtilis may be used to transform B. licheniformis by either protoplast transformation or electroporation. The genes required for the production of isobutanol may be cloned in plasmids pBE20 or pBE60 derivatives (Nagarajan et al., Gene 114:121-126 (1992)). Methods to transform B. licheniformis are known in the art (for example see Fleming et al. Appl. Environ. Microbiol., 61(11):3775-3780 (1995)). The plasmids constructed for expression in B. subtilis may be transformed into B. licheniformis to produce a recombinant microbial host that produces isobutanol.
Expression of an Isobutanol Biosynthetic Pathway in Paenibacillus macerans
Plasmids may be constructed as described above for expression in B. subtilis and used to transform Paenibacillus macerans by protoplast transformation to produce a recombinant microbial host that produces isobutanol.
Expression of the Isobutanol Biosynthetic Pathway in Alcaligenes (Ralstonia) Eutrophus
Methods for gene expression and creation of mutations in Alcaligenes eutrophus are known in the art (see for example Taghavi et al., Appl. Environ. Microbiol., 60(10):3585-3591 (1994)). The genes for an isobutanol biosynthetic pathway may be cloned in any of the broad host range vectors described above, and electroporated to generate recombinants that produce isobutanol. The poly(hydroxybutyrate) pathway in Alcaligenes has been described in detail, a variety of genetic techniques to modify the Alcaligenes eutrophus genome is known, and those tools can be applied for engineering an isobutanol biosynthetic pathway.
Expression of an Isobutanol Biosynthetic Pathway in Pseudomonas putida
Methods for gene expression in Pseudomonas putida are known in the art (see for example Ben-Bassat et al., U.S. Pat. No. 6,586,229, which is incorporated herein by reference). The butanol pathway genes may be inserted into pPCU18 and this ligated DNA may be electroporated into electrocompetent Pseudomonas putida DOT-T1 C5aAR1 cells to generate recombinants that produce isobutanol.
Expression of an Isobutanol Biosynthetic Pathway in Saccharomyces cerevisiae
Methods for gene expression in Saccharomyces cerevisiae are known in the art (see for example Methods in Enzymology, Volume 194, Guide to Yeast Genetics and Molecular and Cell Biology (Part A, 2004, Christine Guthrie and Gerald R. Fink (Eds.), Elsevier Academic Press, San Diego, Calif.). Expression of genes in yeast typically requires a promoter, followed by the gene of interest, and a transcriptional terminator. A number of yeast promoters can be used in constructing expression cassettes for genes encoding an isobutanol biosynthetic pathway, including, but not limited to constitutive promoters FBA, GPD, ADH1, and GPM, and the inducible promoters GAL1, GAL10, and CUP1. Suitable transcriptional terminators include, but are not limited to FBAt, GPDt, GPMt, ERG10t, GAL1t, CYC1, and ADH1. For example, suitable promoters, transcriptional terminators, and the genes of an isobutanol biosynthetic pathway may be cloned into E. coli-yeast shuttle vectors as described in Example 17.
Expression of an Isobutanol Biosynthetic Pathway in Lactobacillus plantarum
The Lactobacillus genus belongs to the Lactobacillales family and many plasmids and vectors used in the transformation of Bacillus subtilis and Streptococcus may be used for lactobacillus. Non-limiting examples of suitable vectors include pAMβ1 and derivatives thereof (Renault et al., Gene 183:175-182 (1996); and O'Sullivan et al., Gene 137:227-231 (1993)); pMBB1 and pHW800, a derivative of pMBB1 (Wyckoff et al. Appl. Environ. Microbiol 62:1481-1486 (1996)); pMG1, a conjugative plasmid (Tanimoto et al., J. Bacteriol. 184:5800-5804 (2002)); pNZ9520 (Kleerebezem et al., Appl. Environ. Microbiol. 63:4581-4584 (1997)); pAM401 (Fujimoto et al., Appl. Environ. Microbiol. 67:1262-1267 (2001)); and pAT392 (Arthur et al., Antimicrob. Agents Chemother. 38:1899-1903 (1994)). Several plasmids from Lactobacillus plantarum have also been reported (e.g., van Kranenburg R, Golic N, Bongers R, Leer R J, de Vos W M, Siezen R J, Kleerebezem M. Appl. Environ. Microbiol. 2005 March; 71(3): 1223-1230). For example, expression of an isobutanol biosynthetic pathway in Lactobacillus plantarum is described in Example 21.
Expression of an Isobutanol Biosynthetic Pathway in Enterococcus faecium, Enterococcus gallinarium, and Enterococcus faecalis
The Enterococcus genus belongs to the Lactobacillales family and many plasmids and vectors used in the transformation of Lactobacillus, Bacillus subtilis, and Streptococcus may be used for Enterococcus. Non-limiting examples of suitable vectors include pAMβ1 and derivatives thereof (Renault et al., Gene 183:175-182 (1996); and O'Sullivan et al., Gene 137:227-231 (1993)); pMBB1 and pHW800, a derivative of pMBB1 (Wyckoff et al. Appl. Environ. Microbiol. 62:1481-1486 (1996)); pMG1, a conjugative plasmid (Tanimoto et al., J. Bacteriol. 184:5800-5804 (2002)); pNZ9520 (Kleerebezem et al., Appl. Environ. Microbiol. 63:4581-4584 (1997)); pAM401 (Fujimoto et al., Appl. Environ. Microbiol. 67:1262-1267 (2001)); and pAT392 (Arthur et al., Antimicrob. Agents Chemother. 38:1899-1903 (1994)). Expression vectors for E. faecalis using the nisA gene from Lactococcus may also be used (Eichenbaum et al., Appl. Environ. Microbiol. 64:2763-2769 (1998). Additionally, vectors for gene replacement in the E. faecium chromosome may be used (Nallaapareddy et al., Appl. Environ. Microbiol. 72:334-345 (2006)). For example, expression of an isobutanol biosynthetic pathway in Enterococcus faecalis is described in Example 22.
Fermentation Media
Fermentation media in the present invention must contain suitable carbon substrates. Suitable substrates may include, but are not limited to, monosaccharides such as glucose and fructose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose or mixtures thereof and unpurified mixtures from renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally the carbon substrate may also be one-carbon substrates such as carbon dioxide, or methanol for which metabolic conversion into key biochemical intermediates has been demonstrated. In addition to one and two carbon substrates methylotrophic organisms are also known to utilize a number of other carbon containing compounds such as methylamine, glucosamine and a variety of amino acids for metabolic activity. For example, methylotrophic yeast are known to utilize the carbon from methylamine to form trehalose or glycerol (Bellion et al., Microb. Growth C1 Compd., [Int. Symp.], 7th (1993), 415-32. Editor(s): Murrell, J. Collin; Kelly, Don P. Publisher: Intercept, Andover, UK). Similarly, various species of Candida will metabolize alanine or oleic acid (Sulter et al., Arch. Microbiol. 153:485-489 (1990)). Hence it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon containing substrates and will only be limited by the choice of organism.
Although it is contemplated that all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention, preferred carbon substrates are glucose, fructose, and sucrose.
In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those skilled in the art, suitable for the growth of the cultures and promotion of the enzymatic pathway necessary for isobutanol production.
Culture Conditions
Typically cells are grown at a temperature in the range of about 25° C. to about 40° C. in an appropriate medium. Suitable growth media in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast medium (YM) broth. Other defined or synthetic growth media may also be used, and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science. The use of agents known to modulate catabolite repression directly or indirectly, e.g., cyclic adenosine 2′:3′-monophosphate, may also be incorporated into the fermentation medium.
Suitable pH ranges for the fermentation are between pH 5.0 to pH 9.0, where pH 6.0 to pH 8.0 is preferred as the initial condition.
Fermentations may be performed under aerobic or anaerobic conditions, where anaerobic or microaerobic conditions are preferred.
The amount of isobutanol produced in the fermentation medium can be determined using a number of methods known in the art, for example, high performance liquid chromatography (HPLC) or gas chromatography (GC).
Industrial Batch and Continuous Fermentations
The present process employs a batch method of fermentation. A classical batch fermentation is a closed system where the composition of the medium is set at the beginning of the fermentation and not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the medium is inoculated with the desired organism or organisms, and fermentation is permitted to occur without adding anything to the system. Typically, however, a “batch” fermentation is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and oxygen concentration. In batch systems the metabolite and biomass compositions of the system change constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are responsible for the bulk of production of end product or intermediate.
A variation on the standard batch system is the Fed-Batch system. Fed-Batch fermentation processes are also suitable in the present invention and comprise a typical batch system with the exception that the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the media. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO2. Batch and Fed-Batch fermentations are common and well known in the art and examples may be found in Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, Mass., or Deshpande, Mukund V., Appl. Biochem. Biotechnol., 36:227, (1992), herein incorporated by reference.
Although the present invention is performed in batch mode it is contemplated that the method would be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.
Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to the medium being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, supra.
It is contemplated that the present invention may be practiced using either batch, fed-batch or continuous processes and that any known mode of fermentation would be suitable. Additionally, it is contemplated that cells may be immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for isobutanol production.
Methods for Isobutanol Isolation from the Fermentation Medium
The bioproduced isobutanol may be isolated from the fermentation medium using methods known in the art. For example, solids may be removed from the fermentation medium by centrifugation, filtration, decantation, or the like. Then, the isobutanol may be isolated from the fermentation medium, which has been treated to remove solids as described above, using methods such as distillation, liquid-liquid extraction, or membrane-based separation. Because isobutanol forms a low boiling point, azeotropic mixture with water, distillation can only be used to separate the mixture up to its azeotropic composition. Distillation may be used in combination with another separation method to obtain separation around the azeotrope. Methods that may be used in combination with distillation to isolate and purify isobutanol include, but are not limited to, decantation, liquid-liquid extraction, adsorption, and membrane-based techniques. Additionally, isobutanol may be isolated using azeotropic distillation using an entrainer (see for example Doherty and Malone, Conceptual Design of Distillation Systems, McGraw Hill, New York, 2001).
The isobutanol-water mixture forms a heterogeneous azeotrope so that distillation may be used in combination with decantation to isolate and purify the isobutanol. In this method, the isobutanol containing fermentation broth is distilled to near the azeotropic composition. Then, the azeotropic mixture is condensed, and the isobutanol is separated from the fermentation medium by decantation. The decanted aqueous phase may be returned to the first distillation column as reflux. The isobutanol-rich decanted organic phase may be further purified by distillation in a second distillation column.
The isobutanol may also be isolated from the fermentation medium using liquid-liquid extraction in combination with distillation. In this method, the isobutanol is extracted from the fermentation broth using liquid-liquid extraction with a suitable solvent. The isobutanol-containing organic phase is then distilled to separate the isobutanol from the solvent.
Distillation in combination with adsorption may also be used to isolate isobutanol from the fermentation medium. In this method, the fermentation broth containing the isobutanol is distilled to near the azeotropic composition and then the remaining water is removed by use of an adsorbent, such as molecular sieves (Aden et al. Lignocellulosic Biomass to Ethanol Process Design and Economics Utilizing Co-Current Dilute Acid Prehydrolysis and Enzymatic Hydrolysis for Corn Stover, Report NREL/TP-510-32438, National Renewable Energy Laboratory, June 2002).
Additionally, distillation in combination with pervaporation may be used to isolate and purify the isobutanol from the fermentation medium. In this method, the fermentation broth containing the isobutanol is distilled to near the azeotropic composition, and then the remaining water is removed by pervaporation through a hydrophilic membrane (Guo et al., J. Membr. Sci. 245, 199-210 (2004)).
The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various uses and conditions.
General Methods
Standard recombinant DNA and molecular cloning techniques used in the Examples are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N.Y. (1989) (Maniatis) and by T. J. Silhavy, M. L. Bennan, and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1984) and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, pub. by Greene Publishing Assoc. and Wiley-Interscience (1987).
Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following Examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), American Society for Microbiology, Washington, D.C. (1994)) or by Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, Mass. (1989). All reagents, restriction enzymes and materials used for the growth and maintenance of bacterial cells were obtained from Aldrich Chemicals (Milwaukee, Wis.), BD Diagnostic Systems (Sparks, Md.), Life Technologies (Rockville, Md.), or Sigma Chemical Company (St. Louis, Mo.) unless otherwise specified.
Microbial strains were obtained from The American Type Culture Collection (ATCC), Manassas, Va., unless otherwise noted.
The oligonucleotide primers to use in the following Examples are given in Table 4. All the oligonucleotide primers are synthesized by Sigma-Genosys (Woodlands, Tex.).
TABLE 4
Oligonucleotide Cloning, Screening, and
Sequencing Primers
SEQ
ID
Name
Sequence
Description
NO:
N80
CACCATGGACAAACAGTATCC
budB
11
GGTACGCC
forward
N81
CGAAGGGCGATAGCTTTACCA
budB
12
ATCC
reverse
N100
CACCATGGCTAACTACTTCAA
ilvC
13
TACACTGA
forward
N101
CCAGGAGAAGGCCTTGAGTGT
ilvC
14
TTTCTCC
reverse
N102
CACCATGCCTAAGTACCGTTC
ilvD
15
CGCCACCA
forward
N103
CGCAGCACTGCTCTTAAATAT
ilvD
16
TCGGC
reverse
N104
CACCATGAACAACTTTAATCT
yqhD
17
GCACACCC
forward
N105
GCTTAGCGGGCGGCTTCGTAT
yqhD
18
ATACGGC
reverse
N110
GCATGCCTTAAGAAAGGAGGG
budB
19
GGGTCACATGGACAAACAGTA
forward
TCC
N111
ATGCATTTAATTAATTACAGA
budB
20
ATCTGACTCAGATGCAGC
reverse
N112
GTCGACGCTAGCAAAGGAGGG
ilvC
21
AATCACCATGGCTAACTACTT
forward
CAA
N113
TCTAGATTAACCCGCAACAGC
ilvC
22
AATACGTTTC
reverse
N114
TCTAGAAAAGGAGGAATAAAG
ilvD
23
TATGCCTAAGTACCGTTC
forward
N115
GGATCCTTATTAACCCCCCAG
ilvD
24
TTTCGATTTA
reverse
N116
GGATCCAAAGGAGGCTAGACA
kivD
25
TATGTATACTGTGGGGGA
forward
N117
GAGCTCTTAGCTTTTATTTTG
kivD
26
CTCCGCAAAC reverse
N118
GAGCTCAAAGGAGGAGCAAGT
yqhD
27
AATGAACAACTTTAATCT
forward
N119
GAATTCACTAGTCCTAGGTTA
yqhD
28
GCGGGCGGCTTCGTATATACG
reverse
G
BenNF
CAACATTAGCGATTTTCTTTT
Npr forward
29
CTCT
BenASR
CATGAAGCTTACTAGTGGGCT
Npr reverse
30
TAAGTTTTGAAAATAATGAAA
AT
N110.2
GAGCTCACTAGTCAATTGTAA
budB
31
GTAAGTAAAAGGAGGTGGGGT
forward
CACATGGACAAACAGTATCC
N111.2
GGATCCGATCGACTTAAGCCT
budB
32
CAGCTTACAGAATCTGACTCA
reverse
GATGCAGC
N112.2
GAGCTCCTTAAGAAGGAGGTA
ilvC
33
ATCACCATGGCTAACTACTTC
forward
AA
N113.2
GGATCCGATCGAGCTAGCGCG
ilvC
34
GCCGCTTAACCCGCAACAGCA
reverse
ATACGTTTC
N114.2
GAGCTCGCTAGCAAGGAGGTA
ilvD
35
TAAAGTATGCCTAAGTACCGT
forward
TC
N115.2
GGATCCGATCGATTAATTAAC
ilvD
36
CTAAGGTTATTAACCCCCCAG
reverse
TTTCGATTTA
N116.2
GAGCTCTTAATTAAAAGGAGG
kivD
37
TTAGACATATGTATACTGTGG
forward
GGGA
N117.2
GGATCCAGATCTCCTAGGACA
kivD
38
TGTTTAGCTTTTATTTTGCTC
reverse
CGCAAAC
N130SeqF1
TGTTCCAACCTGATCACCG
sequencing
40
primer
N130SeqF2
GGAAAACAGCAAGGCGCT
sequencing
41
primer
N130SeqF3
CAGCTGAACCAGTTTGCC
sequencing
42
primer
N130SeqF4
AAAATACCAGCGCCTGTCC
sequencing
43
primer
N130SeqR1
TGAATGGCCACCATGTTG
sequencing
44
primer
N130SeqR2
GAGGATCTCCGCCGCCTG
sequencing
45
primer
N130SeqR3
AGGCCGAGCAGGAAGATC
sequencing
46
primer
N130SeqR4
TGATCAGGTTGGAACAGCC
sequencing
47
primer
N131SeqF1
AAGAACTGATCCCACAGGC
sequencing
48
primer
N131SeqF2
ATCCTGTGCGGTATGTTGC
sequencing
49
primer
N131SeqF3
ATTGCGATGGTGAAAGCG
sequencing
50
primer
N131SeqR1
ATGGTGTTGGCAATCAGCG
sequencing
51
primer
N131SeqR2
GTGCTTCGGTGATGGTTT
sequencing
52
primer
N131SeqR3
TTGAAACCGTGCGAGTAGC
sequencing
53
primer
N132SeqF1
TATTCACTGCCATCTCGCG
sequencing
54
primer
N132SeqF2
CCGTAAGCAGCTGTTCCT
sequencing
55
primer
N132SeqF3
GCTGGAACAATACGACGTTA
sequencing
56
primer
N132SeqF4
TGCTCTACCCAACCAGCTTC
sequencing
57
primer
N132SeqR1
ATGGAAAGACCAGAGGTGCC
sequencing
58
primer
N132SeqR2
TGCCTGTGTGGTACGAAT
sequencing
59
primer
N132SeqR3
TATTACGCGGCAGTGCACT
sequencing
60
primer
N132SeqR4
GGTGATTTTGTCGCAGTTAGA
sequencing
61
G
primer
N133SeqF1
TCGAAATTGTTGGGTCGC
sequencing
62
primer
N133SeqF2
GGTCACGCAGTTCATTTCTAA
sequencing
63
G
primer
N133SeqF3
TGTGGCAAGCCGTAGAAA
sequencing
64
primer
N133SeqF4
AGGATCGCGTGGTGAGTAA
sequencing
65
primer
N133SeqR1
GTAGCCGTCGTTATTGATGA
sequencing
66
primer
N133SeqR2
GCAGCGAACTAATCAGAGATT
sequencing
67
C
primer
N133SeqR3
TGGTCCGATGTATTGGAGG
sequencing
68
primer
N133SeqR4
TCTGCCATATAGCTCGCGT
sequencing
69
primer
Scr1
CCTTTCTTTGTGAATCGG
sequencing
72
primer
Scr2
AGAAACAGGGTGTGATCC
sequencing
73
primer
Scr3
AGTGATCATCACCTGTTGCC
sequencing
74
primer
Scr4
AGCACGGCGAGAGTCGACGG
sequencing
75
primer
T-budB
AGATAGATGGATCCGGAGGTG
budB
144
(BamHI)
GGTCACATGGACAAACAGT
forward
B-kivD
CTCTAGAGGATCCAGACTCCT
kivD
145
(BamHI)
AGGACATG
reverse
T-groE(XhoI)
AGATAGATCTCGAGAGCTATT
PgroE
147
GTAACATAATCGGTACGGGGG
forward
TG
B-groEL(SpeI,
ATTATGTCAGGATCCACTAGT
PgroE
148
BamH1)
TTCCTCCTTTAATTGGGAATT
reverse
GTTATCCGC
T-groEL
AGCTATTGTAACATAATCGGT
PgroE
149
ACGGGGGTG
forward
T-ilvCB.s.
ACATTGATGGATCCCATAACA
ilvC
150
(BamHI)
AGGGAGAGATTGAAATGGTAA
forward
AAG
B-ilvCB.s.
TAGACAACGGATCCACTAGTT
ilvC
151
(SpeIBamHI)
TAATTTTGCGCAACGGAGACC
reverse
ACCGC
T-BD64
TTACCGTGGACTCACCGAGTG
pBD64
152
(DraIII)
GGTAACTAGCCTCGCCGGAAA
forward
GAGCG
B-BD64
TCACAGTTAAGACACCTGGTG
pBD64
153
(DraIII)
CCGTTAATGCGCCATGACAGC
reverse
CATGAT
T-laclq
ACAGATAGATCACCAGGTGCA
laclq
154
(DraIII)
AGCTAATTCCGGTGGAAACGA
forward
GGTCATC
B-laclq
ACAGTACGATACACGGGGTGT
laclq
155
(DraIII)
CACTGCCCGCTTTCCAGTCGG
reverse
GAAACC
T-groE
TCGGATTACGCACCCCGTGAG
PgroE
156
(DraIII)
CTATTGTAACATAATCGGTAC
forward
GGGGGTG
B-B.s.ilvC
CTGCTGATCTCACACCGTGTG
ilvC
157
(DraIII)
TTAATTTTGCGCAACGGAGAC
reverse
CACCGC
T-bdhB
TCGATAGCATACACACGGTGG
bdhB
159
(DraIII)
TTAACAAAGGAGGGGTTAAAA
forward
TGGTTGATTTCG
B-bdhB
ATCTACGCACTCGGTGATAAA
bdhB
160
(rrnBT1DraIII)
ACGAAAGGCCCAGTCTTTCGA
reverse
CTGAGCCTTTTCGTTTTATCT
TACACAGATTTTTTGAATATT
TGTAGGAC
LDH EcoRV F
GACGTCATGACCACCCGCCGA
ldhL
161
TCCCTTTT
forward
LDH AatIIR
GATATCCAACACCAGCGACCG
ldhL
162
ACGTATTAC
reverse
Cm F
ATTTAAATCTCGAGTAGAGGA
Cm forward
163
TCCCAACAAACGAAAATTGGA
TAAAG
Cm R
ACGCGTTATTATAAAAGCCAG
Cm reverse
164
TCATTAGG
P11 F-StuI
CCTAGCGCTATAGTTGTTGAC
P11
165
AGAATGGACATACTATGATAT
promoter
ATTGTTGCTATAGCGA
forward
P11 R-SpeI
CTAGTCGCTATAGCAACAATA
P11
166
TATCATAGTATGTCCATTCTG
promoter
TCAACAACTATAGCGCTAGG
reverse
PldhL F-
AAGCTTGTCGACAAACCAACA
ldhL
167
HindIII
TTATGACGTGTCTGGGC
forward
PldhL R-
GGATCCTCATCCTCTCGTAGT
ldhL
168
BamHI
GAAAATT
reverse
F-bdhB-AvrII
TTCCTAGGAAGGAGGTGGTTA
bdhB
169
AAATGGTTGATTTCG
forward
R-bdhB-
TTGGATCCTTACACAGATTTT
bdhB
170
BamHI
TTGAATAT
reverse
F-ilvC(B.s.)-
AACTTAAGAAGGAGGTGATTG
ilvC
171
AfIII
AAATGGTAAAAGTATATT
forward
R-ilvC(B.s.)-
AAGCGGCCGCTTAATTTTGCG
ivlC
172
NotI
CAACGGAGACC
reverse
F-
TTAAGCTTGACATACTTGAAT
nisA
173
PnisA(HindIII)
GACCTAGTC
promoter
forward
R-PnisA(SpeI
TTGGATCCAAACTAGTATAAT
nisA
174
BamHI)
TTATTTTGTAGTTCCTTC
promoter
reverse
Methods for Determining Isobutanol Concentration in Culture Media
The concentration of isobutanol in the culture media can be determined by a number of methods known in the art. For example, a specific high performance liquid chromatography (HPLC) method utilized a Shodex SH-1011 column with a Shodex SH-G guard column, both purchased from Waters Corporation (Milford, Mass.), with refractive index (RI) detection. Chromatographic separation was achieved using 0.01 M H2SO4 as the mobile phase with a flow rate of 0.5 mL/min and a column temperature of 50° C. Isobutanol had a retention time of 46.6 min under the conditions used. Alternatively, gas chromatography (GC) methods are available. For example, a specific GC method utilized an HP-INNOWax column (30 m×0.53 mm id,1 μm film thickness, Agilent Technologies, Wilmington, Del.), with a flame ionization detector (FID). The carrier gas was helium at a flow rate of 4.5 mL/min, measured at 150° C. with constant head pressure; injector split was 1:25 at 200° C.; oven temperature was 45° C. for 1 min, 45 to 220° C. at 10° C./min, and 220° C. for 5 min; and FID detection was employed at 240° C. with 26 mL/min helium makeup gas. The retention time of isobutanol was 4.5 min.
The meaning of abbreviations is as follows: “s” means second(s), “min” means minute(s), “h” means hour(s), “psi” means pounds per square inch, “nm” means nanometers, “d” means day(s), “μL” means microliter(s), “mL” means milliliter(s), “L” means liter(s), “mm” means millimeter(s), “nm” means nanometers, “mM” means millimolar, “μM” means micromolar, “M” means molar, “mmol” means millimole(s), “μmol” means micromole(s)”, “g” means gram(s), “μg” means microgram(s) and “μg” means nanogram(s), “PCR” means polymerase chain reaction, “OD” means optical density, “OD600” means the optical density measured at a wavelength of 600 nm, “kDa” means kilodaltons, “g” means the gravitation constant, “bp” means base pair(s), “kbp” means kilobase pair(s), “% w/v” means weight/volume percent, % v/v” means volume/volume percent, “IPTG” means isopropyl-β-D-thiogalactopyranoiside, “RBS” means ribosome binding site, “HPLC” means high performance liquid chromatography, and “GC” means gas chromatography. The term “molar selectivity” is the number of moles of product produced per mole of sugar substrate consumed and is reported as a percent.
The purpose of this Example was to clone the budB gene from Klebsiella pneumoniae and express it in E. coli BL21-AI. The budB gene was amplified from Klebsiella pneumoniae strain ATCC 25955 genomic DNA using PCR, resulting in a 1.8 kbp product.
Genomic DNA was prepared using the Gentra Puregene kit (Gentra Systems, Inc., Minneapolis, Minn.; catalog number D-5000A). The budB gene was amplified from Klebsiella pneumoniae genomic DNA by PCR using primers N80 and N81 (see Table 2), given as SEQ ID NOs:11 and 12, respectively. Other PCR amplification reagents were supplied in manufacturers' kits, for example, Finnzymes Phusion™ High-Fidelity PCR Master Mix (New England Biolabs Inc., Beverly, Mass.; catalog no. F-531) and used according to the manufacturer's protocol. Amplification was carried out in a DNA Thermocycler GeneAmp 9700 (PE Applied Biosystems, Foster city, Calif.).
For expression studies the Gateway cloning technology (Invitrogen Corp., Carlsbad, Calif.) was used. The entry vector pENTRSDD-TOPO allowed directional cloning and provided a Shine-Dalgarno sequence for the gene of interest. The destination vector pDEST14 used a T7 promoter for expression of the gene with no tag. The forward primer incorporated four bases (CACC) immediately adjacent to the translational start codon to allow directional cloning into pENTRSDD-TOPO (Invitrogen) to generate the plasmid pENTRSDD-TOPObudB. The pENTR construct was transformed into E. coli Top10 (Invitrogen) cells and plated according to manufacturer's recommendations. Transformants were grown overnight and plasmid DNA was prepared using the QIAprep Spin Miniprep kit (Qiagen, Valencia, Calif.; catalog no.27106) according to manufacturer's recommendations. Clones were sequenced to confirm that the genes inserted in the correct orientation and to confirm the sequence. The nucleotide sequence of the open reading frame (ORF) for this gene and the predicted amino acid sequence of the enzyme are given as SEQ ID NO:1 and SEQ ID NO:2, respectively.
To create an expression clone, the budB gene was transferred to the pDEST 14 vector by recombination to generate pDEST14budB. The pDEST14budB vector was transformed into E. coli BL21-AI cells (Invitrogen). Transformants were inoculated into Luria Bertani (LB) medium supplemented with 50 μg/mL of ampicillin and grown overnight. An aliquot of the overnight culture was used to inoculate 50 mL of LB supplemented with 50 μg/mL of ampicillin. The culture was incubated at 37° C. with shaking until the OD600 reached 0.6-0.8. The culture was split into two 25-mL cultures and arabinose was added to one of the flasks to a final concentration of 0.2% w/v. The negative control flask was not induced with arabinose. The flasks were incubated for 4 h at 37° C. with shaking. Cells were harvested by centrifugation and the cell pellets were resuspended in 50 mM MOPS, pH 7.0 buffer. The cells were disrupted either by sonication or by passage through a French Pressure Cell. The whole cell lysate was centrifuged yielding the supernatant or cell free extract and the pellet or the insoluble fraction. An aliquot of each fraction (whole cell lysate, cell free extract and insoluble fraction) was resuspended in SDS (MES) loading buffer (Invitrogen), heated to 85° C. for 10 min and subjected to SDS-PAGE analysis (NuPAGE 4-12% Bis-Tris Gel, catalog no. NP0322Box, Invitrogen). A protein of the expected molecular weight of about 60 kDa, as deduced from the nucleic acid sequence, was present in the induced culture but not in the uninduced control.
Acetolactate synthase activity in the cell free extracts is measured using the method described by Bauerle et al., (Biochim. Biophys. Acta 92(1):142-149 (1964)).
The purpose of this prophetic Example is to describe how to clone the ilvC gene from E. coli K12 and express it in E. coli BL21-AI. The ilvC gene is amplified from E. coli genomic DNA using PCR.
The ilvC gene is cloned and expressed in the same manner as the budB gene described in Example 1. Genomic DNA from E. coli is prepared using the Gentra Puregene kit (Gentra Systems, Inc., Minneapolis, Minn.; catalog number D-5000A). The ilvC gene is amplified by PCR using primers N100 and N101 (see Table 2), given as SEQ ID NOs:13 and 14, respectively, creating a 1.5 kbp product. The forward primer incorporates four bases (CCAC) immediately adjacent to the translational start codon to allow directional cloning into pENTR/SD/D-TOPO (Invitrogen) to generate the plasmid pENTRSDD-TOPOilvC. Clones are sequenced to confirm that the genes are inserted in the correct orientation and to confirm the sequence. The nucleotide sequence of the open reading frame (ORF) for this gene and the predicted amino acid sequence of the enzyme are given as SEQ ID NO:3 and SEQ ID NO:4, respectively.
To create an expression clone, the ilvC gene is transferred to the pDEST 14 (Invitrogen) vector by recombination to generate pDEST14ilvC. The pDEST14ilvC vector is transformed into E. coli BL21-AI cells and expression from the T7 promoter is induced by addition of arabinose. A protein of the expected molecular weight of about 54 kDa, as deduced from the nucleic acid sequence, is present in the induced culture, but not in the uninduced control.
Acetohydroxy acid reductoisomerase activity in the cell free extracts is measured using the method described by Arfin and Umbarger (J. Biol. Chem. 244(5):1118-1127 (1969)).
The purpose of this prophetic Example is to describe how to clone the ilvD gene from E. coli K12 and express it in E. coli BL21-AI. The ilvD gene is amplified from E. coli genomic DNA using PCR.
The ilvD gene is cloned and expressed in the same manner as the budB gene described in Example 1. Genomic DNA from E. coli is prepared using the Gentra Puregene kit (Gentra Systems, Inc., Minneapolis, Minn.; catalog number D-5000A). The ilvD gene is amplified by PCR using primers N1O2 and N1O3 (see Table 2), given as SEQ ID NOs:15 and 16, respectively, creating a 1.9 kbp product. The forward primer incorporates four bases (CCAC) immediately adjacent to the translational start codon to allow directional cloning into pENTR/SD/D-TOPO (Invitrogen) to generate the plasmid pENTRSDD-TOPOilvD. Clones are submitted for sequencing to confirm that the genes are inserted in the correct orientation and to confirm the sequence. The nucleotide sequence of the open reading frame (ORF) for this gene and the predicted amino acid sequence of the enzyme are given as SEQ ID NO:5 and SEQ ID NO:6, respectively.
To create an expression clone, the ilvD gene is transferred to the pDEST 14 (Invitrogen) vector by recombination to generate pDEST14ilvD. The pDEST14ilvD vector is transformed into E. coli BL21-AI cells and expression from the T7 promoter is induced by addition of arabinose. A protein of the expected molecular weight of about 66 kDa, as deduced from the nucleic acid sequence, is present in the induced culture, but not in the uninduced control.
Acetohydroxy acid dehydratase activity in the cell free extracts is measured using the method described by Flint et al. (J. Biol. Chem. 268(20):14732-14742 (1993)).
The purpose of this prophetic example is to describe how to clone the kivD gene from Lactococcus lactis and express it in E. coli BL21-AI.
A DNA sequence encoding the branched-chain keto acid decarboxylase (kivD) from L. lactis is obtained from GenScript (Piscataway, N.J.). The sequence obtained is codon-optimized for expression in both E. coli and B. subtilis and is cloned into pUC57, to form pUC57-kivD. The codon-optimized nucleotide sequence of the open reading frame (ORF) for this gene and the predicted amino acid sequence of the enzyme are given as SEQ ID NO:7 and SEQ ID NO:8, respectively.
To create an expression clone NdeI and BamHI restriction sites are utilized to clone the 1.7 kbp kivD fragment from pUC57-kivD into vector pET-3a (Novagen, Madison, Wis.). This creates the expression clone pET-3a-kivD. The pET-3a-kivD vector is transformed into E. coli BL21-AI cells and expression from the T7 promoter is induced by addition of arabinose. A protein of the expected molecular weight of about 61 kDa, as deduced from the nucleic acid sequence, is present in the induced culture, but not in the uninduced control.
Branched-chain keto acid decarboxylase activity in the cell free extracts is measured using the method described by Smit et al. (Appl. Microbiol. Biotechnol. 64:396-402 (2003)).
The purpose of this prophetic Example is to describe how to clone the yqhD gene from E. coli K12 and express it in E. coli BL21-AI. The yqhD gene is amplified from E. coli genomic DNA using PCR.
The yqhD gene is cloned and expressed in the same manner as the budB gene described in Example 1. Genomic DNA from E. coli is prepared using the Gentra Puregene kit (Gentra Systems, Inc., Minneapolis, Minn.; catalog number D-5000A). The yqhD gene is amplified by PCR using primers N1O4 and N1O5 (see Table 2), given as SEQ ID NOs:17 and 18, respectively, creating a 1.2 kbp product. The forward primer incorporates four bases (CCAC) immediately adjacent to the translational start codon to allow directional cloning into pENTR/SD/D-TOPO (Invitrogen) to generate the plasmid pENTRSDD-TOPOyqhD. Clones are submitted for sequencing to confirm that the genes are inserted in the correct orientation and to confirm the sequence. The nucleotide sequence of the open reading frame (ORF) for this gene and the predicted amino acid sequence of the enzyme are given as SEQ ID NO 9 and SEQ ID NO:10, respectively.
To create an expression clone, the yqhD gene is transferred to the pDEST 14 (Invitrogen) vector by recombination to generate pDEST14yqhD. The pDEST14ilvD vector is transformed into E. coli BL21-AI cells and expression from the T7 promoter is induced by addition of arabinose. A protein of the expected molecular weight of about 42 kDa, as deduced from the nucleic acid sequence, is present in the induced culture, but not in the uninduced control.
Branched-chain alcohol dehydrogenase activity in the cell free extracts is measured using the method described by Sulzenbacher et al. (J. Mol. Biol. 342(2):489-502 (2004)).
The purpose of this prophetic Example is to describe how to construct a transformation vector comprising the genes encoding the five steps in an isobutanol biosynthetic pathway. All genes are placed in a single operon under the control of a single promoter. The individual genes are amplified by PCR with primers that incorporate restriction sites for later cloning and the forward primers contain an optimized E. coli ribosome binding site (AAAGGAGG). PCR products are TOPO cloned into the pCR 4Blunt-TOPO vector and transformed into E. coli Top10 cells (Invitrogen). Plasmid DNA is prepared from the TOPO clones and the sequence of the genes is verified. Restriction enzymes and T4 DNA ligase (New England Biolabs, Beverly, Mass.) are used according to manufacturer's recommendations. For cloning experiments, restriction fragments are gel-purified using QIAquick Gel Extraction kit (Qiagen). After confirmation of the sequence, the genes are subcloned into a modified pUC 19 vector as a cloning platform. The pUC19 vector is modified by HindIII/SapI digestion, creating pUC19dHS. The digest removes the lac promoter adjacent to the MCS (multiple cloning site), preventing transcription of the operons in the vector.
The budB gene is amplified from K. pneumoniae ATCC 25955 genomic DNA by PCR using primer pair N10 and N111 (see Table 2), given as SEQ ID NOs:19 and 20, respectively, creating a 1.8 kbp product. The forward primer incorporates SphI and AfIII restriction sites and a ribosome binding site (RBS). The reverse primer incorporates PacI and NsiI restriction sites. The PCR product is cloned into pCR4 Blunt-TOPO creating pCR4 Blunt-TOPO-budB. Plasmid DNA is prepared from the TOPO clones and the sequence of the gene is verified.
The ilvC gene is amplified from E. coli K12 genomic DNA by PCR using primer pair N 112 and N113 (see Table 2) given as SEQ ID NOs:21 and 22, respectively, creating a 1.5 kbp product. The forward primer incorporates SaII and NheI restriction sites and a RBS. The reverse primer incorporates a XbaI restriction site. The PCR product is cloned into pCR4 Blunt-TOPO creating pCR4 Blunt-TOPO-ilvC. Plasmid DNA is prepared from the TOPO clones and the sequence of the gene is verified.
The ilvD gene is amplified from E. coli K12 genomic DNA by PCR using primer pair N114 and N115 (see Table 2) given as SEQ ID NOs:23 and 24, respectively, creating a 1.9 kbp product. The forward primer incorporates a XbaI restriction site and a RBS. The reverse primer incorporates a BamHI restriction site. The PCR product is cloned into pCR4 Blunt-TOPO creating pCR4 Blunt-TOPO-ilvD. Plasmid DNA is prepared from the TOPO clones and the sequence of the gene is verified.
The kivD gene is amplified from pUC57-kivD (described in Example 4) by PCR using primer pair N116 and N117 (see Table 2), given as SEQ ID NOs:25 and 26, respectively, creating a 1.7 bp product. The forward primer incorporates a BamHI restriction site and a RBS. The reverse primer incorporates a SacI restriction site. The PCR product is cloned into pCR4 Blunt-TOPO creating pCR4 Blunt-TOPO-kivD. Plasmid DNA is prepared from the TOPO clones and the sequence of the gene is verified.
The yqhD gene is amplified from E. coli K12 genomic DNA by PCR using primer pair N118 and N119 (see Table 2) given as SEQ ID NOs:27 and 28, respectively, creating a 1.2 kbp product. The forward primer incorporates a SacI restriction site. The reverse primer incorporates SpeI and EcoRI restriction sites. The PCR product is cloned into pCR4 Blunt-TOPO creating pCR4 Blunt-TOPO-yqhD. Plasmid DNA is prepared from the TOPO clones and the sequence of the gene is verified.
To construct the isobutanol pathway operon, the yqhD gene is excised from pCR4 Blunt-TOPO-yqhD with SacI and EcoRI, releasing a 1.2 kbp fragment. This is ligated with pUC19dHS, which has previously been digested with SacI and EcoRI. The resulting clone, pUC19dHS-yqhD, is confirmed by restriction digest. Next, the ilvC gene is excised from pCR4 Blunt-TOPO-ilvC with SaII and XbaI, releasing a 1.5 kbp fragment. This is ligated with pUC19dHS-yqhD, which has previously been digested with SaII and XbaI. The resulting clone, pUC19dHS-ilvC-yqhD, is confirmed by restriction digest. The budB gene is then excised from pCR4 Blunt-TOPO-budB with SphI and NsiI, releasing a 1.8 kbp fragment. pUC19dHS-ilvC-yqhD is digested with SphI and PstI and ligated with the SphI/NsiI budB fragment (NsiI and PstI generate compatible ends), forming pUC19dHS-budB-ilvC-yqhD. A 1.9 kbp fragment containing the ilvD gene is excised from pCR4 Blunt-TOPO-ilvD with XbaI and BamHI and ligated with pUC19dHS-budB-ilvC-yqhD, which is digested with these same enzymes, forming pUC19dHS-budB-ilvC-ilvD-yqhD. Finally, kivD is excised from pCR4 Blunt-TOPO-kivD with BamHI and SacI, releasing a 1.7 kbp fragment. This fragment is ligated with pUC19dHS-budB-ilvC-ilvD-yqhD, which has previously been digested with BamHI and SacI, forming pUC19dHS-budB-ilvC-ilvD-kivD-yqhD.
The pUC19dHS-budB-ilvC-ilvD-kivD-yqhD vector is digested with AfIII and SpeI to release a 8.2 kbp operon fragment that is cloned into pBenAS, an E. coli-B. subtilis shuttle vector. Plasmid pBenAS is created by modification of the pBE93 vector, which is described by Nagarajan, (WO 93/24631, Example 4). To make pBenAS the Bacillus amyloliquefaciens neutral protease promoter (NPR), signal sequence, and the phoA gene are removed with a NcoI/HindIII digest of pBE93. The NPR promoter is PCR amplified from pBE93 by primers BenNF and BenASR, given as SEQ ID NOS:29 and 30, respectively. Primer BenASR incorporates AfIII, SpeI, and HindIII sites downstream of the promoter. The PCR product is digested with NcoI and HindIII and the fragment is cloned into the corresponding sites in the vector creating pBenAS. The operon fragment is subcloned into the AfIII and SpeI sites in pBenAS creating pBen-budB-ilvC-ilvD-kivD-yqhD.
The purpose of this prophetic Example is to describe how to express an isobutanol biosynthetic pathway in E. coli.
The plasmid pBen-budB-ilvC-ilvD-kivD-yqhD, constructed as described in Example 6, is transformed into E. coli NM522 (ATCC No. 47000) to give E. coli strain NM522/pBen-budB-ilvC-ilvD-kivD-yqhD and expression of the genes in the operon is monitored by SDS-PAGE analysis, enzyme assay and Western blot analysis. For Western blots, antibodies are raised to synthetic peptides by Sigma-Genosys (The Woodlands, Tex.).
E. coli strain NM522/pBen-budB-ilvC-ilvD-kivD-yqhD is inoculated into a 250 mL shake flask containing 50 mL of medium and shaken at 250 rpm and 35° C. The medium is composed of: glucose (5 g/L), MOPS (0.05 M), ammonium sulfate (0.01 M), potassium phosphate, monobasic (0.005 M), S10 metal mix (1% (v/v)) yeast extract (0.1% (w/v)), casamino acids (0.1% (w/v)), thiamine (0.1 mg/L), proline (0.05 mg/L), and biotin (0.002 mg/L), and is titrated to pH 7.0 with KOH. S10 metal mix contains: MgCl2 (200 mM), CaCl2 (70 mM), MnCl2 (5 mM), FeCl3 (0.1 mM), ZnCl2 (0.1 mM), thiamine hydrochloride (0.2 mM), CuSO4 (172 μM), CoCl2 (253 μM), and Na2MoO4 (242 μM). After 18 h, isobutanol is detected by HPLC or GC analysis, using methods that are well known in the art, for example, as described in the General Methods section above.
The purpose of this prophetic Example is to describe how to express an isobutanol biosynthetic pathway in Bacillus subtilis. The same approach as described in Example 7 is used.
The plasmid pBen-budB-ilvC-ilvD-kivD-yqhD, constructed as described in Example 6, is used. This plasmid is transformed into Bacillus subtilis BE1010 (J. Bacteriol. 173:2278-2282 (1991)) to give B. subtilis strain BE1010/pBen-budB-ilvC-ilvD-kivD-yqhD and expression of the genes in each operon is monitored as described in Example 7.
B. subtilis strain BE1010/pBen-budB-ilvC-ilvD-kivD-yqhD is inoculated into a 250 mL shake flask containing 50 mL of medium and shaken at 250 rpm and 35° C. for 18 h. The medium is composed of: dextrose (5 g/L), MOPS (0.05 M), glutamic acid (0.02 M), ammonium sulfate (0.01 M), potassium phosphate, monobasic buffer (0.005 M), S10 metal mix (as described in Example 11,1% (v/v)), yeast extract (0.1% (w/v)), casamino acids (0.1% (w/v)), tryptophan (50 mg/L), methionine (50 mg/L), and lysine (50 mg/L), and is titrated to pH 7.0 with KOH. After 18 h, isobutanol is detected by HPLC or GC analysis using methods that are well known in the art, for example, as described in the General Methods section above.
To create another acetolactate synthase expression clone, the budB gene was cloned into the vector pTrc99A. The budB gene was first amplified from pENTRSDD-TOPObudB (described in Example 1) using primers (N110.2 and N111.2, given as SEQ ID NOs:31 and 32, respectively) that introduced SacI, SpeI and Mfel sites at the 5′ end and BbvCI, AfIII, and BamHI sites at the 3′ end. The resulting 1.75 kbp PCR product was cloned into pCR4-Blunt TOPO (Invitrogen) and the DNA sequence was confirmed (using N130Seq sequencing primers F1-F4 and R1-R4, given as SEQ ID NOs:40-47, respectively). The budB gene was then excised from this vector using SacI and BamHI and cloned into pTrc99A (Amann et al. Gene 69(2):301-315 (1988)), generating pTrc99A::budB. The pTrc99A::budB vector was transformed into E. coli TOP10 cells and the transformants were inoculated into LB medium supplemented with 50 μg/mL of ampicillin and grown overnight at 37° C. An aliquot of the overnight culture was used to inoculate 50 mL of LB medium supplemented with 50 μg/mL of ampicillin. The culture was incubated at 37° C. with shaking until the OD600 reached 0.6 to 0.8. Expression of budB from the Trc promoter was then induced by the addition of 0.4 mM IPTG. Negative control flasks were also prepared that were not induced with IPTG. The flasks were incubated for 4 h at 37° C. with shaking. Cell-free extracts were prepared as described in Example 1.
Acetolactate synthase activity in the cell free extracts was measured as described in Example 1. Three hours after induction with IPTG, an acetolactate synthase activity of 8 units/mg was detected. The control strain carrying only the pTrc99A plasmid exhibited 0.03 units/mg of acetolactate synthase activity.
The purpose of this Example was to clone the ilvC gene from E. coli K12 and express it in E. coli TOP10. The ilvC gene was amplified from E. coli K12 strain FM5 (ATCC 53911) genomic DNA using PCR.
The ilvC gene was cloned and expressed in a similar manner as described for the cloning and expression of ilvC in Example 2 above. PCR was used to amplify ilvC from the E. coli FM5 genome using primers N112.2 and N113.2 (SEQ ID NOs:33 and 34, respectively). The primers created SacI and AfllII sites and an optimal RBS at the 5′ end and NotI, NheI and BamHI sites at the 3′ end of ilvC. The 1.5 kbp PCR product was cloned into pCR4Blunt TOPO according to the manufacturer's protocol (Invitrogen) generating pCR4Blunt TOPO::ilvC. The sequence of the PCR product was confirmed using sequencing primers (N131SeqF1-F3, and N131SeqR1-R3, given as SEQ ID NOs:48-53, respectively). To create an expression clone, the ilvC gene was excised from pCR4Blunt TOPO::ilvC using SacI and BamHI and cloned into pTrc99A. The pTrc99A::ilvC vector was transformed into E. coli TOP10 cells and expression from the Trc promoter was induced by addition of IPTG, as described in Example 9. Cell-free extracts were prepared as described in Example 1.
Acetohydroxy acid reductoisomerase activity in the cell free extracts was measured as described in Example 2. Three hours after induction with IPTG, an acetohydroxy acid reductoisomerase activity of 0.026 units/mg was detected. The control strain carrying only the pTrc99A plasmid exhibited less than 0.001 units/mg of acetohydroxy acid reductoisomerase activity.
The purpose of this Example was to clone the ilvD gene from E. coli K12 and express it in E. coli Top10. The ilvD gene was amplified from E. coli K12 strain FM5 (ATCC 53911) genomic DNA using PCR.
The ilvD gene was cloned and expressed in a similar manner as the ilvC gene described in Example 10. PCR was used to amplify ilvD from the E. coli FM5 genome using primers N114.2 and N115.2 (SEQ ID NOs:35 and 36, respectively). The primers created SacI and NheI sites and an optimal RBS at the 5′ end and Bsu36I, PacI and BamHI sites at the 3′ end of ilvD. The 1.9 kbp PCR product was cloned into pCR4Blunt TOPO according to the manufacturer's protocol (Invitrogen) generating pCR4Blunt TOPO::ilvD. The sequence of the PCR product was confirmed (sequencing primers N132SeqF1-F4 and N132SeqR1-R4, given as SEQ ID NOs:54-61, respectively). To create an expression clone, the ilvD gene was excised from plasmid pCR4Blunt TOPO::ilvD using SacI and BamHI, and cloned into pTrc99A. The pTrc99A::ilvD vector was transformed into E. coli TOP10 cells and expression from the Trc promoter was induced by addition of IPTG, as described in Example 9. Cell-free extracts were prepared as described in Example 1.
Acetohydroxy acid dehydratase activity in the cell free extracts was measured as described in Example 3. Three hours after induction with IPTG, an acetohydroxy acid dehydratase activity of 46 units/mg was measured. The control strain carrying only the pTrc99A plasmid exhibited no detectable acetohydroxy acid dehydratase activity.
The purpose of this Example was to clone the kivD gene from Lactococcus lactis and express it in E. coli TOP10.
The kivD gene was cloned and expressed in a similar manner as that described for iIvC in Example 10 above. PCR was used to amplify kivD from the plasmid pUC57-kivD (see Example 4, above) using primers N116.2 and N117.2 (SEQ ID NOs:37 and 38, respectively). The primers created SacI and PacI sites and an optimal RBS at the 5′ end and PciI, AvrII, BglII and BamHI sites at the 3′ end of kivD. The 1.7 kbp PCR product was cloned into pCR4Blunt TOPO according to the manufacturer's protocol (Invitrogen) generating pCR4Blunt TOPO::kivD. The sequence of the PCR product was confirmed using primers N133SeqF1-F4 and N133SeqR1-R4 (given as SEQ ID NOs:62-69, respectively). To create an expression clone, the kivD gene was excised from plasmid pCR4Blunt TOPO::kivD using SacI and BamHI, and cloned into pTrc99A. The pTrc99A::kivD vector was transformed into E. coli TOP10 cells and expression from the Trc promoter was induced by addition of IPTG, as described in Example 9. Cell-free extracts were prepared as described in Example 1.
Branched-chain keto acid decarboxylase activity in the cell free extracts was measured as described in Example 4, except that Purpald® reagent (Aldrich, Catalog No.162892) was used to detect and quantify the aldehyde reaction products. Three hours after induction with IPTG, a branched-chain keto acid decarboxylase activity of greater than 3.7 units/mg was detected. The control strain carrying only the pTrc99A plasmid exhibited no detectable branched-chain keto acid decarboxylase activity.
E. coli contains a native gene (yqhD) that was identified as a 1,3-propanediol dehydrogenase (U.S. Pat. No. 6,514,733). The YqhD protein has 40% identity to AdhB (encoded by adhB) from Clostridium, a putative NADH-dependent butanol dehydrogenase. The yqhD gene was placed under the constitutive expression of a variant of the glucose isomerase promoter 1.6GI (SEQ ID NO. 70) in E. coli strain MG1655 1.6yqhD::Cm (WO 2004/033646) using λ Red technology (Datsenko and Wanner, Proc. Natl. Acad. Sci. U.S.A. 97:6640 (2000)). MG1655 1.6yqhD::Cm contains a FRT-CmR-FRT cassette so that the antibiotic marker can be removed. Similarly, the native promoter was replaced by the 1.5GI promoter (WO 2003/089621) (SEQ ID NO. 71), creating strain MG1655 1.5GI-yqhD::Cm, thus, replacing the 1.6GI promoter of MG1655 1.6yqhD::Cm with the 1.5GI promoter.
Strain MG1655 1.5GI-yqhD::Cm was grown in LB medium to mid-log phase and cell free extracts were prepared as described in Example 1. This strain was found to have NADPH-dependent isobutyraldehyde reductase activity when the cell extracts were assayed by following the decrease in absorbance at 340 nm at pH 7.5 and 35° C.
To generate a second expression strain containing 1.5GI yqhD::Cm, a P1 lysate was prepared from MG1655 1.5GI yqhD::Cm and the cassette was transferred to BL21 (DE3) (Invitrogen) by transduction, creating BL21 (DE3) 1.5GI-yqhD::Cm.
The purpose of this Example was to construct a transformation vector comprising the first four genes (i.e., budB, ilvC, ilvD and kivD) in an isobutanol biosynthetic pathway.
To construct the transformation vector, first, the ilvC gene was obtained from pTrc99A::ilvC (described in Example 10) by digestion with AfIII and BamHI and cloned into pTrc99A::budB (described in Example 9), which was digested with AfIII and BamHI to produce plasmid pTrc99A::budB-ilvC. Next, the ilvD and kivD genes were obtained from pTrc99A::ilvD (described in Example 11) and pTrc99A::kivD (described in Example 12), respectively, by digestion with NheI and PacI (ilvD) and PacI and BamHI (kivD). These genes were introduced into pTrc99A::budB-ilvC, which was first digested with NheI and BamHI, by three-way ligation. The presence of all four genes in the final plasmid, pTrc99A::budB-ilvC-ilvD-kivD, was confirmed by PCR screening and restriction digestion.
To create E. coli isobutanol production strains, pTrc99A::budB-ilvC-ilvD-kivD (described in Example 14) was transformed into E. coli MG1655 1.5GI yqhD::Cm and E. coli BL21 (DE3) 1.5GI yqhD::Cm (described in Example 13). Transformants were initially grown in LB medium containing 50 μg/mL kanamycin and 100 μg/mL carbenicillin. The cells from these cultures were used to inoculate shake flasks (approximately 175 mL total volume) containing 50 or 170 mL of TM3a/glucose medium (with appropriate antibiotics) to represent high and low oxygen conditions, respectively. TM3a/glucose medium contained (per liter): glucose (10 g), KH2PO4(13.6 g), citric acid monohydrate (2.0 g), (NH4)2SO4(3.0 g), MgSO4.7H2O (2.0 g), CaCl2.2H2O (0.2 g), ferric ammonium citrate (0.33 g), thiamine.HCl (1.0 mg), yeast extract (0.50 g), and 10 mL of trace elements solution. The pH was adjusted to 6.8 with NH4OH. The trace elements solution contained: citric acid.H2O (4.0 g/L), MnSO4.H2O (3.0 g/L), NaCl (1.0 g/L), FeSO4.7H2O (0.10 g/L), COCl2.6H2O (0.10 g/L), ZnSO4.7H2O (0.10 g/L), CuSO4.5H2O (0.010 g/L), H3BO3 (0.010 g/L), and Na2MoO4. 2H2O (0.010 g/L).
The flasks were inoculated at a starting OD600 of <0.01 units and incubated at 34° C. with shaking at 300 rpm. The flasks containing 50 mL of medium were closed with 0.2 μm filter caps; the flasks containing 150 mL of medium were closed with sealed caps. IPTG was added to a final concentration of 0.04 mM when the cells reached an OD600 of ≧0.4 units. Approximately 18 h after induction, an aliquot of the broth was analyzed by HPLC (Shodex Sugar SH1011 column (Showa Denko America, Inc. NY) with refractive index (RI) detection) and GC (Varian CP-WAX 58(FFAP) CB, 0.25 mm×0.2 μm×25 μm (Varian, Inc., Palo Alto, Calif.) with flame ionization detection (FID)) for isobutanol content, as described in the General Methods section. No isobutanol was detected in control strains carrying only the pTrc99A vector (results not shown). Molar selectivities and titers of isobutanol produced by strains carrying pTrc99A::budB-ilvC-ilvD-kivD are shown in Table 5. Significantly higher titers of isobutanol were obtained in the cultures grown under low oxygen conditions.
TABLE 5
Production of Isobutanol by E. coli Strains Grown on Glucose
Molar
O2
Isobutanol
Selectivity
Strain
Conditions
mM*
(%)
MG1655 1.5Gl yqhD/
High
0.4
4.2
pTrc99A::budB-ilvC-ilvD-kivD
MG1655 1.5Gl yqhD/
Low
9.9
39
pTrc99A::budB-ilvC-ilvD-kivD
BL21 (DE3) 1.5Gl yqhD/
High
0.3
3.9
pTrc99A::budB-ilvC-ilvD-kivD
BL21 (DE3) 1.5Gl yqhD/
Low
1.2
12
pTrc99A::budB-ilvC-ilvD-kivD
*Determined by HPLC.
Since the strains described in Example 15 were not capable of growth on sucrose, an additional plasmid was constructed to allow utilization of sucrose for isobutanol production. A sucrose utilization gene cluster cscBKA, given as SEQ ID NO:39, was isolated from genomic DNA of a sucrose-utilizing E. coli strain derived from ATCC strain 13281. The sucrose utilization genes (cscA, cscK, and cscB) encode a sucrose hydrolase (CscA), given as SEQ ID NO:139, D-fructokinase (CscK), given as SEQ ID NO:140, and sucrose permease (CscB), given as SEQ ID NO:141. The sucrose-specific repressor gene cscR was not included so that the three genes cscBKA were expressed constitutively from their native promoters in E. coli.
Genomic DNA from the sucrose-utilizing E. coli strain was digested to completion with BamHI and EcoRI. Fragments having an average size of about 4 kbp were isolated from an agarose gel and were ligated to plasmid pLitmus28 (New England Biolabs), digested with BamHI and EcoRI and transformed into ultracompetent E. coli TOP10F′ cells (Invitrogen). The transformants were streaked onto MacConkey agar plates containing 1% sucrose and ampicillin (100 μg/mL) and screened for the appearance of purple colonies. Plasmid DNA was isolated from the purple transformants, and sequenced with M13 Forward and Reverse primers (Invitrogen), and Scr1-4 (given as SEQ ID NOs:72-75, respectively). The plasmid containing cscB, cscK, and cscA (cscBKA) genes was designated pScr1.
To create a sucrose utilization plasmid that was compatible with the isobutanol pathway plasmid (Example 14), the operon from pScr1 was subcloned into pBHR1 (MoBiTec, Goettingen, Germany). The cscBKA genes were isolated by digestion of pScr1 with XhoI (followed by incubation with Klenow enzyme to generate blunt ends) and then by digestion with AgeI. The resulting 4.2 kbp fragment was ligated into pBHR1 that had been digested with NaeI and AgeI, resulting in the 9.3 kbp plasmid pBHR1::cscBKA.
The sucrose plasmid pBHR1::cscBKA was transformed into E. coli BL21 (DE3) 1.5 yqhD/pTrc99A::budB-ilvC-ilvD-kivD and E. coli MG1655 1.5yqhD/pTrc99A::budB-ilvC-ilvD-kivD (described in Example 15) by electroporation. Transformants were first selected on LB medium containing 100 μg/mL ampicillin and 50 μg/mL kanamycin and then screened on MacConkey sucrose (1%) plates to confirm functional expression of the sucrose operon. For production of isobutanol, strains were grown in TM3a minimal defined medium (described in Example 15) containing 1% sucrose instead of glucose, and the culture medium was analyzed for the amount of isobutanol produced, as described in Example 15, except that samples were taken 14 h after induction. Again, no isobutanol was detected in control strains carrying only the pTrc99A vector (results not shown). Molar selectivities and titers of isobutanol produced by MG1655 1.5yqhD carrying pTrc99A::budB-ilvC-ilvD-kivD are shown in Table 6. Similar results were obtained with the analogous BL21 (DE3) strain.
TABLE 6
Production of Isobutanol by E. coli strain MG1655 1.5yqhD/pTrc99A::
budB-ilvC-ilvD-kivD/pBHR1::cscBKA Grown on Sucrose
Isobutanol,
O2 Conditions
IPTG, mM
mM*
Molar Selectivity, %
High
0.04
0.17
2
High
0.4
1.59
21
Low
0.04
4.03
26
Low
0.4
3.95
29
*Determined by HPLC.
To express isobutanol pathway genes in Saccharomyces cerevisiae, a number of E. coli-yeast shuttle vectors were constructed. A PCR approach (Yu, et al. Fungal Genet. Biol. 41:973-981 (2004)) was used to fuse genes with yeast promoters and terminators. Specifically, the GPD promoter (SEQ ID NO:76) and CYC1 terminator (SEQ ID NO:77) were fused to the alsS gene from Bacillus subtilis (SEQ ID NO:78), the FBA promoter (SEQ ID NO:79) and CYC1 terminator were fused to the ILV5 gene from S. cerevisiae (SEQ ID NO:80), the ADH1 promoter (SEQ ID NO:81) and ADH1 terminator (SEQ ID NO:82) were fused to the ILV3 gene from S. cerevisiae (SEQ ID NO:83), and the GPM promoter (SEQ ID NO:84) and ADH1 terminator were fused to the kivD gene from Lactococcus lactis (SEQ ID NO:7). The primers, given in Table 7, were designed to include restriction sites for cloning promoter/gene/terminator products into E. coli-yeast shuttle vectors from the pRS400 series (Christianson et al. Gene 110:119-122 (1992)) and for exchanging promoters between constructs. Primers for the 5′ ends of ILV5 and ILV3 (N138 and N155, respectively, given as SEQ ID NOs: 95 and 107, respectively) generated new start codons to eliminate mitochondrial targeting of these enzymes.
All fused PCR products were first cloned into pCR4-Blunt by TOPO cloning reaction (Invitrogen) and the sequences were confirmed (using M13 forward and reverse primers (Invitrogen) and the sequencing primers provided in Table 7. Two additional promoters (CUP1 and GAL1) were cloned by TOPO reaction into pCR4-Blunt and confirmed by sequencing; primer sequences are indicated in Table 7. The plasmids that were constructed are described in Table 8. The plasmids were transformed into either Saccharomyces cerevisiae BY4743 (ATCC 201390) or YJR148w (ATCC 4036939) to assess enzyme specific activities using the enzyme assays described in Examples 1-4 and Examples 9-12. For the determination of enzyme activities, cultures were grown to an OD600 of 1.0 in synthetic complete medium (Methods in Yeast Genetics, 2005, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp. 201-202) lacking any metabolite(s) necessary for selection of the expression plasmid(s), harvested by centrifugation (2600×g for 8 min at 4° C.), washed with buffer, centrifuged again, and frozen at −80° C. The cells were thawed, resuspended in 20 mM Tris-HCl, pH 8.0 to a final volume of 2 mL, and then disrupted using a bead beater with 1.2 g of glass beads (0.5 mm size). Each sample was processed on high speed for 3 minutes total (with incubation on ice after each minute of beating). Extracts were cleared of cell debris by centrifugation (20,000×g for 10 min at 4° C.).
TABLE 7
Primer Sequences for Cloning and
Sequencing of S. cerevisiae Expression
Vectors
SEQ
ID
Name
Sequence
Description
NO:
N98SeqF1
CGTGTTAGTCACATCAGGA
B. subtilis alsS
85
C
sequencing primer
N98SeqF2
GGCCATAGCAAAAATCCAA
B. subtilis alsS
86
ACAGC
sequencing primer
N98SeqF3
CCACGATCAATCATATCGA
B. subtilis alsS
87
ACACG
sequencing primer
N98SeqF4
GGTTTCTGTCTCTGGTGAC
B. subtilis alsS
88
AAG
sequencing primer
N99SeqR1
GTCTGGTGATTCTACGCGC
B. subtilis alsS
89
AAG
sequencing primer
N99SeqR2
CATCGACTGCATTACGCAA
B. subtilis alsS
90
CTC
sequencing primer
N99SeqR3
CGATCGTCAGAACAACATC
B. subtilis alsS
91
TGC
sequencing primer
N99SeqR4
CCTTCAGTGTTCGCTGTCA
B. subtilis alsS
92
G
sequencing primer
N136
CCGCGGATAGATCTGAAAT
FBA promoter
93
GAATAACAATACTGACA
forward primer
with SacII/BglII
sites
N137
TACCACCGAAGTTGATTTG
FBA promoter
94
CTTCAACATCCTCAGCTCT
reverse primer
AGATTTGAATATGTATTAC
with BbvCl site
TTGGTTAT
and ILV5-
annealing region
N138
ATGTTGAAGCAAATCAACT
ILV5 forward
95
TCGGTGGTA
primer (creates
alternate start
codon)
N139
TTATTGGTTTTCTGGTCTC
ILV5 reverse
96
AAC
primer
N140
AAGTTGAGACCAGAAAACC
CYC terminator
97
AATAATTAATTAATCATGT
forward primer
AATTAGTTATGTCACGCTT
with PacI site and
ILV5-annealing
region
N141
GCGGCCGCCCGCAAATTAA
CYC terminator
98
AGCCTTCGAGC
reverse primer
with NotI site
N142
GGATCCGCATGCTTGCATT
GPM promoter
99
TAGTCGTGC
forward primer
with BamHI site
N143
CAGGTAATCCCCCACAGTA
GPM promoter
100
TACATCCTCAGCTATTGTA
reverse primer
ATATGTGTGTTTGTTTGG
with BbvCl site
and kivD-
annealing region
N144
ATGTATACTGTGGGGGATT
kivD forward
101
ACC
primer
N145
TTAGCTTTTATTTTGCTCC
kivD reverse
102
GCA
primer
N146
TTTGCGGAGCAAAATAAAA
ADH terminator
103
GCTAATTAATTAAGAGTAA
forward primer
GCGAATTTCTTATGATTTA
with PacI site and
kivD-annealing
region
N147
ACTAGTACCACAGGTGTTG
ADH terminator
104
TCCTCTGAG
reverse primer
with SpeI site
N151
CTAGAGAGCTTTCGTTTTC
alsS reverse
105
ATG
primer
N152
CTCATGAAAACGAAAGCTC
CYC terminator
106
TCTAGTTAATTAATCATGT
forward primer
AATTAGTTATGTCACGCTT
with PacI site and
alsS-annealing
region
N155
ATGGCAAAGAAGCTCAACA
ILV3 forward
107
AGTACT
primer (alternate
start codon)
N156
TCAAGCATCTAAAACACAA
ILV3 reverse
108
CCG
primer
N157
AACGGTTGTGTTTTAGATG
ADH terminator
109
CTTGATTAATTAAGAGTAA
forward primer
GCGAATTTCTTATGATTTA
with PacI site and
ILV3-annealing
region
N158
GGATCCTTTTCTGGCAACC
ADH promoter
110
AAACCCATA
forward primer
with BamHI site
N159
CGAGTACTTGTTGAGCTTC
ADH promoter
111
TTTGCCATCCTCAGCGAGA
reverse primer
TAGTTGATTGTATGCTTG
with BbvCl site
and ILV3-
annealing region
N160SeqF1
GAAAACGTGGCATCCTCTC
FBA::ILV5::CYC
112
sequencing primer
N160SeqF2
GCTGACTGGCCAAGAGAAA
FBA::ILV5::CYC
113
sequencing primer
N160SeqF3
TGTACTTCTCCCACGGTTT
FBA::ILV5::CYC
114
C
sequencing primer
N160SeqF4
AGCTACCCAATCTCTATAC
FBA::ILV5::CYC
115
CCA
sequencing primer
N160SeqF5
CCTGAAGTCTAGGTCCCTA
FBA::ILV5::CYC
116
TTT
sequencing primer
N160SeqR1
GCGTGAATGTAAGCGTGAC
FBA::ILV5::CYC
117
sequencing primer
N160SeqR2
CGTCGTATTGAGCCAAGAA
FBA::ILV5::CYC
118
C
sequencing primer
N160SeqR3
GCATCGGACAACAAGTTCA
FBA::ILV5::CYC
119
T
sequencing primer
N160SeqR4
TCGTTCTTGAAGTAGTCCA
FBA::ILV5::CYC
120
ACA
sequencing primer
N160SeqR5
TGAGCCCGAAAGAGAGGAT
FBA::ILV5::CYC
121
sequencing primer
N161SeqF1
ACGGTATACGGCCTTCCTT
ADH:ILV3::ADH
122
sequencing primer
N161SeqF2
GGGTTTGAAAGCTATGCAG
ADH::ILV3::ADH
123
T
sequencing primer
N161SeqF3
GGTGGTATGTATACTGCCA
ADH::ILV3::ADH
124
ACA
sequencing primer
N161SeqF4
GGTGGTACCCAATCTGTGA
ADH:ILV3::ADH
125
TTA
sequencing primer
N161SeqF5
CGGTTTGGGTAAAGATGTT
ADH::ILV3::ADH
126
G
sequencing primer
N161SeqF6
AAACGAAAATTCTTATTCT
ADH::ILV3::ADH
127
TGA
sequencing primer
N161SeqR1
TCGTTTTAAAACCTAAGAG
ADH::ILV3::ADH
128
TCA
sequencing primer
N161SeqR2
CCAAACCGTAACCCATCAG
ADH::ILV3::ADH
129
sequencing primer
N161SeqR3
CACAGATTGGGTACCACCA
ADH::ILV3::ADH
130
sequencing primer
N161SeqR4
ACCACAAGAACCAGGACCT
ADH::ILV3::ADH
131
G
sequencing primer
N161SeqR5
CATAGCTTTCAAACCCGCT
ADH::ILV3::ADH
132
sequencing primer
N161SeqR6
CGTATACCGTTGCTCATTA
ADH::ILV3::ADH
133
GAG
sequencing primer
N162
ATGTTGACAAAAGCAACAA
alsS forward
134
AAGA
primer
N189
ATCCGCGGATAGATCTAGT
GPD forward
135
TCGAGTTTATCATTATCAA
primer with
SacII/BglII sites
N190.1
TTCTTTTGTTGCTTTTGTC
GPD promoter
136
AACATCCTCAGCGTTTATG
reverse primer
TGTGTTTATTCGAAA
with BbvCl site
and alsS-
annealing region
N176
ATCCGCGGATAGATCTATT
GAL1 promoter
137
AGAAGCCGCCGAGCGGGCG
forward primer
with SacII/BglII
sites
N177
ATCCTCAGCTTTTCTCCTT
GAL1 promoter
138
GACGTTAAAGTA
reverse with BbvCl
site
N191
ATCCGCGGATAGATCTCCC
CUP1 promoter
175
ATTACCGACATTTGGGCGC
forward primer
with SacII/BglII
sites
N192
ATCCTCAGCGATGATTGAT
CUP1 promoter
176
TGATTGATTGTA
reverse with BbvCl
site
TABLE 8
E. coli-Yeast Shuttle Vectors Carrying Isobutanol Pathway Genes
Plasmid Name
Construction
pRS426 [ATCC No. 77107],
—
URA3 selection
pRS426::GPD::alsS::CYC
GPD::alsS::CYC PCR product digested with SaclI/NotI
cloned into pRS426 digested with same
pRS426::FBA::ILV5::CYC
FBA::ILV5::CYC PCR product digested with SaclI/NotI
cloned into pRS426 digested with same
pRS425 [ATCC No. 77106],
—
LEU2 selection
pRS425::ADH::ILV3::ADH
ADH::ILV3::ADH PCR product digested with
BamHI/SpeI cloned into pRS425 digested with
same
pRS425::GPM::kivD::ADH
GPM::kivD::ADH PCR product digested with
BamHl/SpeI cloned into pRS425 digested with
same
pRS426::CUP1::alsS
7.7 kbp SaclI/BbvCI fragment from
pRS426::GPD::alsS::CYC ligated with SaclI/BbvCI
CUP1 fragment
pRS426::GAL1::ILV5
7 kbp SaclI/BbvCI fragment from
pRS426::FBA::ILV5:CYC ligated with SaclI/BbvCI
GAL1 fragment
pRS425::FBA::ILV3
8.9 kbp BamHI/BbvCI fragment from
pRS425::ADH::ILV3::ADH ligated with 0.65 kbp
Bg/II/BbvCI FBA fragment from
pRS426::FBA::ILV5::CYC
pRS425::CUP1-alsS+FBA-
2.4 kbp SaclI/NotI fragment from
ILV3
pRS426::CUP1::alsS cloned into
pRS425::FBA::ILV3 cut with SaclI/NotI
pRS426::FBA-ILV5+GPM-
2.7 kbp BamHI/SpeI fragment from
kivD
pRS425::GPM::kivD::ADH cloned into
pRS426::FBA::ILV5::CYC cut with BamHI/SpeI
pRS426::GAL1-FBA+GPM-
8.5 kbp SaclI/NotI fragment from pRS426::FBA-
kivD
ILV5+GPM-kivD ligated with 1.8 kbp SaclI/NotI
fragment from pRS426::GAL1::ILV5
pRS423 [ATCC No. 77104],
—
HIS3 selection
pRS423::CUP1-alsS+FBA-
5.2 kbp Sacl/SalI fragment from pRS425::CUP1-
ILV3
alsS+FBA-ILV3 ligated into pRS423 cut with
Sacl/SalI
pHR81 [ATCC No. 87541],
—
URA3 and leu2-d selection
pHR81::FBA-ILV5+GPM-
4.7 kbp Sacl/BamHI fragment from pRS426::FBA-
kivD
ILV5+GPM-kivD ligated into pHR81 cut with
Sacl/BamHl
Plasmids pRS423::CUP1-alsS+FBA-ILV3 and pHR81::FBA-ILV5+GPM-kivD (described in Example 17) were transformed into Saccharomyces cerevisiae YJR148w to produce strain YJR148w/pRS423::CUP1-alsS+FBA-ILV3/pHR81:: FBA-ILV5+GPM-kivD. A control strain was prepared by transforming vectors pRS423 and pHR81 (described in Example 17) into Saccharomyces cerevisiae YJR148w (strain YJR148w/pRS423/pHR81). Strains were maintained on standard S. cerevisiae synthetic complete medium (Methods in Yeast Genetics, 2005, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp. 201-202) containing either 2% glucose or sucrose but lacking uracil and histidine to ensure maintenance of plasmids.
For isobutanol production, cells were transferred to synthetic complete medium lacking uracil, histidine and leucine. Removal of leucine from the medium was intended to trigger an increase in copy number of the pHR81-based plasmid due to poor transcription of the leu2-d allele (Erhart and Hollenberg, J. Bacteriol. 156:625-635 (1983)). Aerobic cultures were grown in 175 mL capacity flasks containing 50 mL of medium in an Innova4000 incubator (New Brunswick Scientific, Edison, N.J.) at 30° C. and 200 rpm. Low oxygen cultures were prepared by adding 45 mL of medium to 60 mL serum vials that were sealed with crimped caps after inoculation and kept at 30° C. Sterile syringes were used for sampling and addition of inducer, as needed. Approximately 24 h after inoculation, the inducer CuSO4 was added to a final concentration of 0.03 mM. Control cultures for each strain without CuSO4 addition were also prepared. Culture supernatants were analyzed 18 or 19 h and 35 h after CuSO4 addition by both GC and HPLC for isobutanol content, as described above in Example 15. The results for S. cerevisiae YJR148w/pRS423::CUP1-alsS+FBA-ILV3/pHR81::FBA-ILV5+GPM-kivD grown on glucose are presented in Table 9. For the results given in Table 9, the samples from the aerobic cultures were taken at 35 h and the samples from the low oxygen cultures were taken at 19 h and measured by HPLC.
The results for S. cerevisiae YJR148w/pRS423::CUP1-alsS+FBA-ILV3/pHR81::FBA-ILV5+GPM-kivD grown on sucrose are presented in Table 10. The results in this table were obtained with samples taken at 18 h and measured by HPLC.
TABLE 9
Production of Isobutanol by S. cerevisiae YJR148w/pRS423::CUP1-
alsS+FBA-ILV3/pHR81::FBA-ILV5+GPM-kivD Grown on Glucose
Molar Selectivity
Strain
O2 level
Isobutanol, mM
%
YJR148w/pRS423/pHR81 (control)
Aerobic
0.12
0.04
YJR148w/pRS423/pHR81 (control)
Aerobic
0.11
0.04
YJR148w/pRS423::CUP1-alsS+FBA-
Aerobic
0.97
0.34
ILV3/pHR81::FBA-ILV5+ GPM-kivD a
YJR148w/pRS423::CUP1-alsS+FBA-
Aerobic
0.93
0.33
ILV3/pHR81::FBA-ILV5+ GPM-kivD b
YJR148w/pRS423::CUP1-alsS+FBA-
Aerobic
0.85
0.30
ILV3/pHR81::FBA-ILV5+ GPM-kivD c
YJR148w/pRS423/pHR81 (control)
Low
0.11
0.1
YJR148w/pRS423/pHR81 (control)
Low
0.08
0.1
YJR148w/pRS423::CUP1-alsS+FBA-
Low
0.28
0.5
ILV3/pHR81::FBA-ILV5+ GPM-kivD a
YJR148w/pRS423::CUP1-alsS+FBA-
Low
0.20
0.3
ILV3/pHR81::FBA-ILV5+ GPM-kivD b
YJR148w/pRS423::CUP1-alsS+FBA-
Low
0.33
0.6
ILV3/pHR81::FBA-ILV5+ GPM-kivD c
TABLE 10
Production of Isobutanol by S. cerevisiae YJR148w/pRS423::CUP1-
alsS+FBA-ILV3/pHR81::FBA-ILV5+GPM-kivD Grown on Sucrose
Isobutanol
Strain
O2 Level
mM
Molar Selectivity, %
YJR148w/pRS423/pHR81 (control)
Aerobic
0.32
0.6
YJR148w/pRS423/pHR81 (control)
Aerobic
0.17
0.3
YJR148w/pRS423::CUP1-alsS+FBA-
Aerobic
0.68
1.7
ILV3/pHR81::FBA-ILV5+ GPM-kivD a
YJR148w/pRS423::CUP1-alsS+FBA-
Aerobic
0.54
1.2
ILV3/pHR81::FBA-ILV5+ GPM-kivD b
YJR148w/pRS423::CUP1-alsS+FBA-
Aerobic
0.92
2.0
ILV3/pHR81::FBA-ILV5+ GPM-kivD c
YJR148w/pRS423/pHR81 (control)
Low
0.18
0.3
YJR148w/pRS423/pHR81 (control)
Low
0.15
0.3
YJR148w/pRS423::CUP1-alsS+FBA-
Low
0.27
1.2
ILV3/pHRB1::FBA-ILV5+ GPM-kivD a
YJR148w/pRS423::CUP1-alsS+FBA-
Low
0.30
1.1
ILV3/pHR81::FBA-ILV5+ GPM-kivD b
YJR148w/pRS423::CUP1-alsS+FBA-
Low
0.21
0.8
ILV3/pHR81::FBA-ILV5+ GPM-kivD c
Strain suffixes “a”, “b”, and “c” indicate separate isolates.
The results indicate that, when grown on glucose or sucrose under both aerobic and low oxygen conditions, strain YJR148w/pRS423::CUP1-alsS+FBA-ILV3/pHR81::FBA-ILV5+GPM-kivD produced consistently higher levels of isobutanol than the control strain.
Plasmids pRS425::CUP1-alsS+FBA-ILV3 and pRS426::GAL1-ILV5+GPM-kivD (described in Example 17) were transformed into Saccharomyces cerevisiae YJR148w to produce strain YJR148w/pRS425::CUP1-alsS+FBA-ILV3/pRS426::GAL1-ILV5+GPM-kivD. A control strain was prepared by transforming vectors pRS425 and pRS426 (described in Example 17) into Saccharomyces cerevisiae YJR148w (strain YJR148w/pRS425/pRS426). Strains were maintained on synthetic complete medium, as described in Example 18.
For isobutanol production, cells were transferred to synthetic complete medium containing 2% galactose and 1% raffinose, and lacking uracil and leucine. Aerobic and low oxygen cultures were prepared as described in Example 18. Approximately 12 h after inoculation, the inducer CuSO4 was added up to a final concentration of 0.5 mM. Control cultures for each strain without CuSO4 addition were also prepared. Culture supernatants were sampled 23 h after CuSO4 addition for determination of isobutanol by HPLC, as described in Example 18. The results are presented in Table 11. Due to the widely different final optical densities observed and associated with quantifying the residual carbon source, the concentration of isobutanol per OD600 unit (instead of molar selectivities) is provided in the table to allow comparison of strains containing the isobutanol biosynthetic pathway genes with the controls.
TABLE 11
Production of Isobutanol by S. cerevisiae YJR148w/pRS425::CUP1-
alsS+FBA-ILV3/pRS426::GAL1-ILV5+GPM-kivD Grown on Galactose and
Raffinose
Isobutanol
mM Isobutanol
Strain
O2 level
CuSO4, mM
mM
per OD unit
YJR148w/pRS425/pRS426
Aerobic
0.1
0.12
0.01
(control)
YJR148w/pRS425/pRS426
Aerobic
0.5
0.13
0.01
(control)
YJR148w/pRS425::CUP1-alsS+
Aerobic
0
0.20
0.03
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD a
YJR148w/pRS425::CUP1-alsS+
Aerobic
0.03
0.82
0.09
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD b
YJR148w/pRS425::CUP1-alsS+
Aerobic
0.1
0.81
0.09
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD c
YJR148w/pRS425::CUP1-alsS+
Aerobic
0.5
0.16
0.04
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD d
YJR148w/pRS425::CUP1-alsS+
Aerobic
0.5
0.18
0.01
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD e
YJR148w/pRS425/pRS426
Low
0.1
0.042
0.007
(control)
YJR148w/pRS425/pRS426
Low
0.5
0.023
0.006
(control)
YJR148w/pRS425::CUP1-alsS+
Low
0
0.1
0.04
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD a
YJR148w/pRS425::CUP1-alsS+
Low
0.03
0.024
0.02
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD b
YJR148w/pRS425::CUP1-alsS+
Low
0.1
0.030
0.04
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD c
YJR148w/pRS425::CUP1-alsS+
Low
0.5
0.008
0.02
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD d
YJR148w/pRS425::CUP1-alsS+
Low
0.5
0.008
0.004
FBA-ILV3/pRS426::GAL1-ILV5+
GPM-kivD e
Strain suffixes “a”, “b”, “c”, “d” and “e” indicate separate isolates.
The results indicate that in general, higher levels of isobutanol per optical density unit were produced by the YJR148w/pRS425::CUP1-alsS+FBA-ILV3/pRS426::GAL1-ILV5+GPM-kivD strain compared to the control strain under both aerobic and low oxygen conditions.
The purpose of this Example was to express an isobutanol biosynthetic pathway in Bacillus subtilis. The five genes of the isobutanol pathway (pathway steps (a) through (e) in
Integration of the three genes, budB, ilvD and kivD into the chromosome of B. subtilis BE1010. Bacillus integration vectors pFP988DssPspac and pFP988DssPgroE were used for the chromosomal integration of the three genes, budB (SEQ ID NO:1), ilvD (SEQ ID NO:5), and kivD (SEQ ID NO:7). Both plasmids contain an E. coli replicon from pBR322, an ampicillin antibiotic marker for selection in E. coli and two sections of homology to the sacB gene in the Bacillus chromosome that direct integration of the vector and intervening sequence by homologous recombination. Between the sacB homology regions is a spac promoter (PgroE) on pFP988DssPspac or a groEL promoter (PgroE) on pFP988DssPgroE, and a selectable marker for Bacillus, erythromycin. The promoter region also contains the lacO sequence for regulation of expression by a lacI repressor protein. The sequences of pFP988DssPspac (6,341 bp) and pFP988DssPgroE (6,221 bp) are given as SEQ ID NO:142 and SEQ ID NO:143 respectively.
The cassette with three genes budB-ilvD-kivD was constructed by deleting the ilvC gene from plasmid pTrc99a budB-ilvC-ilvD-kivD. The construction of the plasmid pTrc99A::budB-ilvC-ilvD-kivD is described in Example 14. Plasmid pTrc99A::budB-ilvC-ilvD-kivD was digested with AfIII and NheI, treated with the Klenow fragment of DNA polymerase to make blunt ends, and the resulting 9.4 kbp fragment containing pTrc99a vector, budB, ilvD, and kivD was gel-purified. The 9.4 kbp vector fragment was self-ligated to create pTrc99A::budB-ilvD-kivD, and transformed into DH5α competent cells (Invitrogen). A clone of pTrc99a budB-ilvD-kivD was confirmed for the ilvC gene deletion by restriction mapping. The resulting plasmid pTrc99A::budB-ilvD-kivD was digested with SacI and treated with the Klenow fragment of DNA polymerase to make blunt ends. The plasmid was then digested with BamHI and the resulting 5,297 bp budB-ilvD-kivD fragment was gel-purified. The 5,297 bp budB-ilvD-kivD fragment was ligated into the SmaI and BamHI sites of the integration vector pFP988DssPspac. The ligation mixture was transformed into DH5a competent cells. Transformants were screened by PCR amplification of the 5.3 kbp budB-ilvD-kivD fragment with primers T-budB(BamHI) (SEQ ID NO:144) and B-kivD(BamHI) (SEQ ID NO:145). The correct clone was named pFP988DssPspac-budB-ilvD-kivD.
Plasmid pFP988DssPspac-budB-ilvD-kivD was prepared from the E. colitransformant, and transformed into B. subtilis BE1010 competent cells, which had been prepared as described by Doyle et al. (J. Bacteriol. 144:957 (1980)). Competent cells were harvested by centrifugation and the cell pellets were resuspended in a small volume of the supernatant. To one volume of competent cells, two volumes of SPII-EGTA medium (Methods for General and Molecular Bacteriology, P. Gerhardt et al., Ed., American Society for Microbiology, Washington, D.C. (1994)) was added. Aliquots (0.3 mL) of cells were dispensed into test tubes and then 2 to 3 μg of plasmid pFP988DssPspac-budB-ilvD-kivD was added to the tubes. The tubes were incubated for 30 min at 37° C. with shaking, after which 0.1 mL of 10% yeast extract was added to each tube and they were further incubated for 60 min. Transformants were grown for selection on LB plates containing erythromycin (1.0 μg/mL) using the double agar overlay method (Methods for General and Molecular Bacteriology, supra). Transformants were screened by PCR amplification with primers N130SeqF1 (SEQ ID NO:40) and N130SeqR1 (SEQ ID NO:44) for budB, and N133SeqF1 (SEQ ID NO:62) and N133SeqR1 (SEQ ID NO:66) for kivD. Positive integrants showed the expected 1.7 kbp budB and 1.7 kbp kivD PCR products. Two positive integrants were identified and named B. subtilis BE1010 ΔsacB::Pspac-budB-ilvD-kivD #2-3-2 and B. subtilis BE1010 ΔsacB::Pspac-budB-ilvD-kivD #6-12-7.
Assay of the enzyme activities in integrants B. subtilis BE1010 ΔsacB::Pspac-budB-ilvD-kivD #2-3-2 and B. subtilis BE1010 ΔsacB::Pspac-budB-ilvD-kivD #6-12-7 indicated that the activities of BudB, IlvD and KivD were low under the control of the spac promoter (Pspac). To improve expression of functional enzymes, the Pspac promoter was replaced by a PgroE promoter from plasmid pHT01 (MoBitec, Goettingen, Germany).
A 6,039 bp pFP988Dss vector fragment, given as SEQ ID NO:146, was excised from an unrelated plasmid by restriction digestion with XhoI and BamHI, and was gel-purified. The PgroE promoter was PCR-amplified from plasmid pHT01 with primers T-groE(XhoI) (SEQ ID NO:147) and B-groEL(SpeI,BamHI) (SEQ ID NO:148). The PCR product was digested with XhoI and BamHI, ligated with the 6,039 bp pFP988Dss vector fragment, and transformed into DH5α competent cells. Transformants were screened by PCR amplification with primers T-groE(XhoI) and B-groEL(SpeI,BamH1). Positive clones showed the expected 174 bp PgroE PCR product and were named pFP988DssPgroE. The plasmid pFP988DssPgroE was also confirmed by DNA sequence.
Plasmid pFP988DssPspac-budB-ilvD-kivD was digested with SpeI and PmeI and the resulting 5,313 bp budB-ilvD-kivD fragment was gel-purified. The budB-ilvD-kivD fragment was ligated into SpeI and PmeI sites of pFP988DssPgroE and transformed into DH5Δ competent cells. Positive clones were screened for a 1,690 bp PCR product by PCR amplification with primers T-groEL (SEQ ID NO:149) and N111 (SEQ ID NO:20). The positive clone was named pFP988DssPgroE-budB-ilvD-kivD.
Plasmid pFP988DssPgroE-budB-ilvD-kivD was prepared from the E. coli transformant, and transformed into Bacillus subtilis BE1010 competent cells as described above. Transformants were screened by PCR amplification with primers N130SeqF1 (SEQ ID NO:40) and N130SeqR1 (SEQ ID NO:44) for budB, and N133SeqF1 (SEQ ID NO:62) and N133SeqR1 (SEQ ID NO:66) for kivD. Positive integrants showed the expected 1.7 kbp budB and 1.7 kbp kivD PCR products. Two positive integrants were isolated and named B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #1-7 and B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #8-16.
Plasmid Expression of ilvC and bdhB genes. Two remaining isobutanol genes, ilvC and bdhB, were expressed from a plasmid. Plasmid pHT01 (MoBitec), a Bacillus-E. coli shuttle vector, was used to fuse an ilvC gene from B. subtilis to a PgroE promoter so that the ilvC gene was expressed from the PgroE promoter containing a lacO sequence. The ilvC gene, given as SEQ ID NO:186, was PCR-amplified from B. subtilis BR151 (ATCC 33677) genomic DNA with primers T-ilvCB.s.(BamHI) (SEQ ID NO:150) and B-ilvCB.s.(SpeI BamHI) (SEQ ID NO:151). The 1,067 bp ilvC PCR product was digested with BamHI and ligated into the BamHI site of pHT01. The ligation mixture was transformed into DH5α competent cells. Positive clones were screened for a 1,188 bp PCR product by PCR amplification with primers T-groEL and B-ilvB.s.(SpeI BamHI). The positive clone was named pHT01-ilvC(B.s). Plasmid pHT01-ilvC(B.s) was used as a template for PCR amplification of the PgroE-ilvC fused fragment.
Plasmid pBD64 (Minton et al., Nucleic Acids Res. 18:1651(1990)) is a fairly stable vector for expression of foreign genes in B. subtilis and contains a repB gene and chloramphenicol and kanamycin resistance genes for selection in B. subtilis. This plasmid was used for expression of ilvC and bdhB under the control of a PgroE promoter. To clone PgroE-iIvC, bdhB and a lacI repressor gene into plasmid pBD64, a one-step assembly method was used (Tsuge et al., Nucleic Acids Res. 31: e133 (2003)). A 3,588 bp pBD64 fragment containing a repB gene, which included the replication function, and the kanamycin antibiotic marker was PCR-amplified from pBD64 with primers T-BD64(DraIII) (SEQ ID NO:152), which introduced a DraIII sequence (CACCGAGTG), and B-BD64(DraIII) (SEQ ID NO:153), which introduced a DraIII sequence (CACCTGGTG). A 1,327 bp lacI repressor gene was PCR-amplified from pMUTIN4 (Vagner et al., Microbiol. 144:3097-3104 (1998)) with T-lacIq(DraIII) (SEQ ID NO:154), which introduced a DraIII sequence (CACCAGGTG) and B-lacIq(DraIII) (SEQ ID NO:155), which introduced a DraIII sequence (CACGGGGTG). A 1,224 bp PgroE-ilvC fused cassette was PCR-amplified from pHT01-ilvC(B.s) with T-groE(DraIII) (SEQ ID NO:156), which introduced a DraIII sequence (CACCCCGTG), and B-B.s.ilvC(DraIII) (SEQ ID NO:157), which introduced a DraIII sequence (CACCGTGTG). A 1.2 kbp bdhB gene (SEQ ID NO:158) was PCR-amplified from Clostridium acetobutylicum (ATCC 824) genomic DNA with primers T-bdhB(DraIII) (SEQ ID NO:159), which introduced a DraIII sequence (CACACGGTG), and B-bdhB(rrnBT1DraIII) (SEQ ID NO:160), which introduced a DraIII sequence (CACTCGGTG). The three underlined letters in the variable region of the DraIII recognition sequences were designed for specific base-pairing to assemble the four fragments with an order of pBD64-lacI-PgroEilvC-bdhB. Each PCR product with DraIII sites at both ends was digested separately with DraIII, and the resulting DraIII fragments, 3,588 bp pBD64, lacI, PgroEilvC, and bdhB were gel-purified using a QIAGEN gel extraction kit (QIAGEN). A mixture containing an equimolar concentration of each fragment with a total DNA concentration of 30 to 50 μg/100 μL was prepared for ligation. The ligation solution was then incubated at 16° C. overnight. The ligation generated high molecular weight tandem repeat DNA. The ligated long, linear DNA mixture was directly transformed into competent B. subtilis BE1010, prepared as described above. B. subtilis preferentially takes up long repeated linear DNA forms, rather than circular DNA to establish a plasmid. After transformation the culture was spread onto an LB plate containing 10 μg/mL of kanamycin for selection. Positive recombinant plasmids were screened by DraIII digestion, giving four fragments with an expected size of 3,588 bp (pBD64), 1,327 bp (lacI), 1,224 bp (PgorE-ifvC), and 1,194 bp (bdhB). The positive plasmid was named pBDPgroE-ilvC(B.s.)-bdhB.
Demonstration of isobutanol production from glucose or sucrose by B. subtilis BE1010 ΔsacB::PqroE-budB-ilvD-kivD/pBDPqroE-ilvC(B.s.)-bdhB. To construct the recombinant B. subtilis expressing the five genes of the isobutanol biosynthetic pathway, competent cells of the two integrants B. subtilis BE1010 ΔsacB-PgroE-budB-ilvD-kivD #1-7 and B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #8-16 were prepared as described above, and transformed with plasmid pBDPgroE-ilvC(B.s.)-bdhB, yielding B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #1-7/pBDPgroE-ilvC(B.s.)-bdhB and B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #8-16/pBDPgroE-ilvC(B.s.)-bdhB.
The two recombinant strains were inoculated in either 25 mL or 100 mL of glucose medium containing kanamycin (10 μg/mL) in 125 mL flasks to simulate high and low oxygen conditions, respectively, and aerobically grown at 37° C. with shaking at 200 rpm. The medium consisted of 10 mM (NH4)2SO4, 5 mM potassium phosphate buffer (pH 7.0), 100 mM MOPS/KOH buffer (pH 7.0), 20 mM glutamic acid/KOH (pH 7.0), 2% S10 metal mix, 1% glucose, 0.01% yeast extract, 0.01% casamino acids, and 50 μg/mL each of L-tryptophan, L-methionine, and L-lysine. The S10 metal mix consisted of 200 mM MgCl2, 70 mM CaCl2, 5 mM MnCl2, 0.1 mM FeCl3, 0.1 mM ZnCl2, 0.2 mM thiamine hydrochloride, 0.172 mM CuSO4, 0.253 mM COCl2, and 0.242 mM Na2MoO4. The cells were induced with 1.0 mM isopropyl-β-D-thiogalactopyranoiside (IPTG) at early-log phase (OD600 of approximately 0.2). At 24 h after inoculation, an aliquot of the broth was analyzed by HPLC (Shodex Sugar SH1011 column) with refractive index (RI) detection for isobutanol content, as described in the General Methods section. The HPLC results are shown in Table 12.
TABLE 12
Production of Isobutanol from Glucose by B. subtilis BE1010
ΔsacB::PgroE-budB-ilvD-kivD/pBDPgroE-ilvC(B.s.)-bdhB Strains
isobutanol,
Strain
O2 Level
mM
molar selectivity, %
B. subtilis a
high
1.00
1.8
(induced)
B. subtilis b
high
0.87
1.6
(induced)
B. subtilis a
low
0.06
0.1
(induced)
B. subtilis b
low
0.14
0.3
(induced)
B. subtilis a is B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #1-7/pBDPgroE-ilvC(B.s.)-bdhB
B. subtilis b is B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #8-16/pBDPgroE-ilvC(B.s.)-bdhB
The isolate of B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #1-7/pBDPgroE-ilvC(B.s.)-bdhB was also examined for isobutanol production from sucrose, essentially as described above. The recombinant strain was inoculated in 25 mL or 75 mL of sucrose medium containing kanamycin (10 μg/mL) in 125 mL flasks to simulate high and medium oxygen levels, and grown at 37° C. with shaking at 200 rpm. The sucrose medium was identical to the glucose medium except that glucose (10 g/L) was replaced with 10 g/L of sucrose. The cells were uninduced, or induced with 1.0 mM isopropyl-β-D-thiogalactopyranoiside (IPTG) at early-log phase (OD600 of approximately 0.2). At 24 h after inoculation, an aliquot of the broth was analyzed by HPLC (Shodex Sugar SH1011 column) with refractive index (RI) detection for isobutanol content, as described in the General Methods section. The HPLC results are given in Table 13.
TABLE 13
Production of Isobutanol from Sucrose by B. subtilis Strain BE1010
ΔsacB::PgroE-budB-ilvD-kivD/pBDPgroE-ilvC(B.s.)-bdhB
Strain
O2 Level
isobutanol, mM
molar selectivity, %
B. subtilis a
high
Not detected
Not detected
(uninduced)
B. subtilis a
high
0.44
4.9
(induced)
B. subtilis a
medium
0.83
8.6
(induced)
B. subtilis a is B. subtilis BE1010 ΔsacB::PgroE-budB-ilvD-kivD #1-7/pBDPgroE-ilvC(B.s.)-bdhB
The purpose of this prophetic Example is to describe how to express an isobutanol biosynthetic pathway in Lactobacillus plantarum. The five genes of the isobutanol pathway, encoding five enzyme activities, are divided into two operons for expression. The budB, ilvD and kivD genes, encoding the enzymes acetolactate synthase, acetohydroxy acid dehydratase, and branched-chain α-keto acid decarboxylase, respectively, are integrated into the chromosome of Lactobacillus plantarum by homologous recombination using the method described by Hols et al. (Appl Environ. Microbiol. 60:1401-1413 (1994)). The remaining two genes (ilvC and bdhB, encoding the enzymes acetohydroxy acid reductoisomerase and butanol dehydrogenase, respectively) are cloned into an expression plasmid and transformed into the Lactobacillus strain carrying the integrated isobutanol genes. Lactobacillus plantarum is grown in MRS medium (Difco Laboratories, Detroit, Mich.) at 37° C., and chromosomal DNA is isolated as described by Moreira et al. (BMC Microbiol. 5:15 (2005)).
Integration. The budB-ilvD-kivD cassette under the control of the synthetic P11 promoter (Rud et al., Microbiology 152:1011-1019 (2006)) is integrated into the chromosome of Lactobacillus plantarum ATCC BAA-793 (NCIMB 8826) at the ldhL1 locus by homologous recombination. To build the ldhL integration targeting vector, a DNA fragment from Lactobacillus plantarum (Genbank NC—004567) with homology to ldhL is PCR amplified with primers LDH EcoRV F (SEQ ID NO:161) and LDH AatIIR (SEQ ID NO:162). The 1986 bp PCR fragment is cloned into pCR4Blunt-TOPO and sequenced. The pCR4Blunt-TOPO-ldhL1 clone is digested with EcoRV and AatII releasing a 1982 bp ldhL1 fragment that is gel-purified. The integration vector pFP988, given as SEQ ID NO:177, is digested with HindIII and treated with Klenow DNA polymerase to blunt the ends. The linearized plasmid is then digested with AatII and the 2931 bp vector fragment is gel purified. The EcoRV/AatII ldhL1fragment is ligated with the pFP988 vector fragment and transformed into E. coli Top10 cells. Transformants are selected on LB agar plates containing ampicillin (100 μg/mL) and are screened by colony PCR to confirm construction of pFP988-ldhL.
To add a selectable marker to the integrating DNA, the Cm gene with its promoter is PCR amplified from pC194 (GenBank NC—002013, SEQ ID NO:267) with primers Cm F (SEQ ID NO:163) and Cm R (SEQ ID NO:164), amplifying a 836 bp PCR product. This PCR product is cloned into pCR4Blunt-TOPO and transformed into E. coli Top10 cells, creating pCR4Blunt-TOPO-Cm. After sequencing to confirm that no errors are introduced by PCR, the Cm cassette is digested from pCR4Blunt-TOPO-Cm as an 828 bp MluI/SwaI fragment and is gel purified. The ldhL-homology containing integration vector pFP988-ldhL is digested with MluI and SwaI and the 4740 bp vector fragment is gel purified. The Cm cassette fragment is ligated with the pFP988-ldhL vector creating pFP988-DldhL::Cm.
Finally the budB-ilvD-kivD cassette from pFP988DssPspac-budB-ilvD-kivD, described in Example 20, is modified to replace the amylase promoter with the synthetic P11 promoter. Then, the whole operon is moved into pFP988-DldhL::Cm. The P11 promoter is built by oligonucleotide annealing with primer P11 F-StuI (SEQ ID NO:165) and P11 R-SpeI (SEQ ID NO:166). The annealed oligonucleotide is gel-purified on a 6% Ultra PAGE gel (Embi Tec, San Diego, Calif.). The plasmid pFP988DssPspac-budB-ilvD-kivD, containing the amylase promoter, is digested with StuI and SpeI and the resulting 10.9 kbp vector fragment is gel-purified. The isolated P11 fragment is ligated with the digested pFP988DssPspac-budB-ilvD-kivD to create pFP988-P11-budB-ilvD-kivD. Plasmid pFP988-P11-budB-ilvD-kivD is then digested with StuI and BamHI and the resulting 5.4 kbp P11-budB-ilvD-kivD fragment is gel-purified. pFP988-DldhL::Cm is digested with HpaI and BamHI and the 5.5 kbp vector fragment isolated. The budB-ilvD-kivD operon is ligated with the integration vector pFP988-DldhL::Cm to create pFP988-DldhL-P11-budB-ilvD-kivD::Cm.
Integration of pFP988-DldhL-P11-budB-ilvD-kivD::Cm into L. plantarum BAA-793 to form L. plantarum ΔldhL1::budB-ilvD-kivD::Cm comprising exogenous budB, ilvD, and kivD genes. Electrocompetent cells of L. plantarum are prepared as described by Aukrust, T. W., et al. (In: Electroporation Protocols for Microorganisms; Nickoloff, J. A., Ed.; Methods in Molecular Biology, Vol. 47; Humana Press, Inc., Totowa, N.J., 1995, pp 201-208). After electroporation, cells are outgrown in MRSSM medium (MRS medium supplemented with 0.5 M sucrose and 0.1 M MgCl2) as described by Aukrust et al. supra for 2 h at 37° C. without shaking. Electroporated cells are plated for selection on MRS plates containing chloramphenicol (10 μg/mL) and incubated at 37° C. Transformants are initially screened by colony PCR amplification to confirm integration, and initial positive clones are then more rigorously screened by PCR amplification with a battery of primers.
Plasmid Expression of ilvC and bdhB genes. The remaining two isobutanol genes are expressed from plasmid pTRKH3 (O'Sullivan DJ and Klaenhammer TR, Gene 137:227-231 (1993)) under the control of the L. plantarum ldhL promoter (Ferain et al., J. Bacteriol. 176:596-601 (1994)). The ldhL promoter is PCR amplified from the genome of L. plantarum ATCC BAA-793 using primers PldhL F-HindIII (SEQ ID NO:167) and PldhL R-BamHI (SEQ ID NO:168). The 411 bp PCR product is cloned into pCR4Blunt-TOPO and sequenced. The resulting plasmid, pCR4Blunt-TOPO-PldhL is digested with HindIII and BamHI releasing the PldhL fragment.
Plasmid pTRKH3 is digested with HindIII and SphI and the gel-purified vector fragment is ligated with the PldhL fragment and the gel-purified 2.4 kbp BamHI/SphI fragment containing ilvC(B.s.)-bdhB from the Bacillus expression plasmid pBDPgroE-ilvC(B.s.)-bdhB (Example 20) in a three-way ligation. The ligation mixture is transformed into E. coli Top 10 cells and transformants are grown on Brain Heart Infusion (BHI, Difco Laboratories, Detroit, Mich.) plates containing erythromycin (150 mg/L). Transformants are screened by PCR to confirm construction. The resulting expression plasmid, pTRKH3-ilvC(B.s.)-bdhB is transformed into L. plantarum ΔldhL1::budB-ilvD-kivD::Cm by electroporation, as described above.
L. plantarum ΔldhL1::budB-ilvD-kivD::Cm containing pTRKH3-ilvC(B.s.)-bdhB is inoculated into a 250 mL shake flask containing 50 mL of MRS medium plus erythromycin (10 μg/mL) and grown at 37° C. for 18 to 24 h without shaking, after which isobutanol is detected by HPLC or GC analysis, as described in the General Methods section.
The purpose of this prophetic Example is to describe how to express an isobutanol biosynthetic pathway in Enterococcus faecalis. The complete genome sequence of Enterococcus faecalis strain V583, which is used as the host strain for the expression of the isobutanol biosynthetic pathway in this Example, has been published (Paulsen et al., Science 299:2071-2074 (2003)). An E. coli/Gram-positive shuttle vector, Plasmid pTRKH3 (O'Sullivan DJ and Klaenhammer TR, Gene 137:227-231 (1993)), is used for expression of the five genes (budB, ilvC, ilvD, kivD, bdhB) of the isobutanol pathway in one operon. pTRKH3 contains an E. coli plasmid p15A replication origin, the pAMβ1 replicon, and two antibiotic resistance selection markers for tetracycline and erythromycin. Tetracycline resistance is only expressed in E. coli, and erythromycin resistance is expressed in both E. coli and Gram-positive bacteria. Plasmid pAMβ1 derivatives can replicate in E. faecalis (Poyart et al., FEMS Microbiol. Lett. 156:193-198 (1997)). The inducible nisA promoter (PnisA), which has been used for efficient control of gene expression by nisin in a variety of Gram-positive bacteria including Enterococcus faecalis (Eichenbaum et al., Appl. Environ. Microbiol. 64:2763-2769 (1998)), is used to control expression of the five desired genes encoding the enzymes of the isobutanol biosynthetic pathway.
The plasmid pTrc99A::budB-ilvC-ilvD-kivD (described in Example 14), which contains the isobutanol pathway operon, is modified to replace the E. coli ilvC gene (SEQ ID NO:3) with the B. subtilis ilvC gene (SEQ ID NO:184). Additionally, the bdhB gene(SEQ ID NO:158) from Clostridium acetobutylicum is added to the end of the operon. First, the bdhB gene from pBDPgroE-ilvC(B.s.)-bdhB (described in Example 20) is amplified using primers F-bdhB-AvrII (SEQ ID NO:169) and R-bdhB-BamHI (SEQ ID NO:170), and then TOPO cloned and sequenced. The 1194 bp bdhB fragment is isolated by digestion with AvrII and BamHI, followed by gel purification. This bdhB fragment is ligated with pTrc99A::budB-ilvC-ilvD-kivD that has previously been digested with AvrII and BamHI and the resulting fragment is gel purified. The ligation mixture is transformed into E. coli Top 10 cells by electroporation and transformants are selected following overnight growth at 37° C. on LB agar plates containing ampicillin (100 μg/mL). The transformants are then screened by colony PCR to confirm the correct clone containing pTrc99A::budB-ilvC-ilvD-kivD-bdhB.
Next, ilvC(B.s.) is amplified from pBDPgroE-ilvC(B.s.)-bdhB (described in Example 20) using primers F-ilvC(B.s.)-AfIII (SEQ ID NO:171) and R-ilvC(B.s.)-NotI (SEQ ID NO:172). The PCR product is TOPO cloned and sequenced. The 1051 bp ilvC(B.s.) fragment is isolated by digestion with AfIII and NotI followed by gel purification. This fragment is ligated with pTrc99A::budB-ilvC-ilvD-kivD-bdhB that has been cut with AfIII and NotI to release the E. coli ilvC (the 10.7 kbp vector band is gel purified prior to ligation with ilvC(B.s.)). The ligation mixture is transformed into E. coliTop10 cells by electroporation and transformants are selected following overnight growth at 37° C. on LB agar plates containing ampicillin (100 μg/mL). The transformants are then screened by colony PCR to confirm the correct clone containing pTrc99A::budB-ilvC(B.s.)-ilvD-kivD-bdhB.
To provide a promoter for the E. colil Gram-positive shuttle vector pTRKH3, the nisA promoter (Chandrapati et al., Mol. Microbiol. 46(2):467-477 (2002)) is PCR-amplified from Lactococcus lactis genomic DNA with primers F-PnisA(HindIII) (SEQ ID NO:173) and R-PnisA(SpeI BamHI) (SEQ ID NO:174) and then TOPO cloned. After sequencing, the 213 bp nisA promoter fragment is isolated by digestion with HindIII and BamHI followed by gel purification. Plasmid pTRKH3 is digested with HindIII and BamHI and the vector fragment is gel-purified. The linearized pTRKH3 is ligated with the PnisA fragment and transformed into E. coli Top10 cells by electroporation. Transformants are selected following overnight growth at 37° C. on LB agar plates containing erythromycin (25 μg/mL). The transformants are then screened by colony PCR to confirm the correct clone of pTRKH3-PnisA.
Plasmid pTRKH3-PnisA is digested with SpeI and BamHI, and the vector is gel-purified. Plasmid pTrc99A::budB-ilvC(B.s)-ilvD-kivD-bdhB, described above, is digested with SpeI and BamHI, and the 7.5 kbp fragment is gel-purified. The 7.5 kbp budB-ilvC(B.s)-ilvD-kivD-bdhB fragment is ligated into the pTRKH3-PnisA vector at the SpeI and BamHI sites. The ligation mixture is transformed into E. coli Top10 cells by electroporation and transformants are selected following overnight growth on LB agar plates containing erythromycin (25 μg/mL) at 37° C. The transformants are then screened by colony PCR. The resulting plasmid is named pTRKH3-PnisA-budB-ilvC(B.s)-ilvD-kivD-bdhB. This plasmid is prepared from the E. colitransformants and transformed into electrocompetent E. faecalis V583 cells by electroporation using methods known in the art (Aukrust, T. W., et al. In: Electroporation Protocols for Microorganisms; Nickoloff, J. A., Ed.; Methods in Molecular Biology, Vol. 47; Humana Press, Inc., Totowa, N.J., 1995, pp 217-226), resulting in E. faecalis V583/pTRKH3-PnisA-budB-ilvC(B.s)-ilvD-kivD-bdhB.
The second plasmid containing nisA regulatory genes, nisR and nisK, the add9 spectinomycin resistance gene, and the pSH71 origin of replication is transformed into E. faecalis V583/pTRKH3-PnisA-budB-ilvC(B.s)-ilvD-kivD-bdhB by electroporation. The plasmid containing pSH71 origin of replication is compatible with pAMβ1 derivatives in E. faecalis (Eichenbaum et al., supra). Double drug resistant transformants are selected on LB agar plates containing erythromycin (25 μg/mL) and spectinomycin (100 μg/mL), grown at 37° C.
The resulting E. faecalis strain V583B harboring two plasmids, i.e., an expression plasmid (pTRKH3-PnisA-budB-ilvC(B.s)-ilvD-kivD-bdhB) and a regulatory plasmid (pSH71-nisRK), is inoculated into a 250 mL shake flask containing 50 mL of Todd-Hewitt broth supplemented with yeast extract (0.2%) (Fischetti et al., J. Exp. Med. 161:1384-1401 (1985)), nisin (20 μg/mL) (Eichenbaum et al., supra), erythromycin (25 μg/mL), and spectinomycin (100 μg/mL). The flask is incubated without shaking at 37° C. for 18-24 h, after which time, isobutanol production is measured by HPLC or GC analysis, as described in the General Methods section.
Nagarajan, Vasantha, Maggio-Hall, Lori Ann, Flint, Dennis, Donaldson, Gail K., Eliot, Andrew C.
| Patent | Priority | Assignee | Title |
| 10006058, | Jun 18 2010 | GEVO, INC | Recombinant host cells comprising phosphoketalase |
| 10150974, | Jun 28 2013 | Green Biologics Limited | Solvent production |
| 10174345, | Sep 26 2012 | GEVO, INC | Polypeptides with ketol-acid reductoisomerase activity |
| 10184139, | Sep 07 2010 | GEVO, INC | Integration of a polynucleotide encoding a polypeptide that catalyzes pyruvate to acetolactate conversion |
| 10227623, | Nov 24 2013 | DUPONT US HOLDING, LLC | High force and high stress destructuring of cellulosic biomass |
| 10280438, | Aug 11 2014 | GEVO, INC | Method for the production of yeast |
| 10287566, | Mar 15 2013 | GEVO, INC | DHAD variants and methods of screening |
| 10308910, | Jul 03 2013 | GEVO, INC | Partial adaption for butanol production |
| 10308964, | Feb 17 2010 | GEVO, INC | Activity of Fe—S cluster requiring proteins |
| 10450589, | Mar 14 2011 | Easel Biotechnologies, LLC | Microbial synthesis of aldehydes and corresponding alcohols |
| 10570430, | Jul 12 2010 | INBIOSE N V | Metabolically engineered organisms for the production of added value bio-products |
| 10604774, | Sep 21 2012 | GEVO, INC | Production of renewable hydrocarbon compositions |
| 10808265, | Sep 26 2018 | NANTBIO, INC. | Microbes and methods for improved conversion of a feedstock |
| 10876137, | Mar 14 2013 | PRECIGEN, INC | Biological production of multi-carbon compounds from methane |
| 11384374, | Jul 12 2010 | INBIOSE N.V. | Metabolically engineered organisms for the production of added value bio-products |
| 11421235, | Apr 28 2017 | PRECIGEN, INC | Methods and microorganisms for the fermentation of methane to multi-carbon compounds |
| 11821019, | Mar 14 2013 | PRECIGEN, INC. | Biological production of multi-carbon compounds from methane |
| 7993889, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 8017376, | Nov 24 2009 | GEVO, INC | Methods of increasing dihydroxy acid dehydratase activity to improve production of fuels, chemicals, and amino acids |
| 8071358, | Nov 24 2009 | Gevo, Inc. | Methods of increasing dihydroxy acid dehydratase activity to improve production of fuels, chemicals, and amino acids |
| 8133715, | Feb 12 2010 | Gevo, Inc. | Reduced by-product accumulation for improved production of isobutanol |
| 8153415, | Feb 12 2010 | Gevo, Inc. | Reduced by-product accumulation for improved production of isobutanol |
| 8158404, | Feb 12 2010 | Gevo, Inc. | Reduced by-product accumulation for improved production of isobutanol |
| 8178328, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 8198056, | Oct 04 2007 | CONSORCIO BAL BIOFUELS SA | Biofuel production |
| 8211689, | Oct 04 2007 | CONSORCIO BAL BIOFUELS SA | Biofuel production |
| 8222017, | Dec 20 2007 | GEVO, INC | Ketol-acid reductoisomerase using NADH |
| 8241878, | Sep 29 2008 | GEVO, INC | Recombinant yeast host cell with Fe-S cluster proteins and methods of using thereof |
| 8273558, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 8273565, | Nov 24 2009 | Gevo, Inc. | Methods of increasing dihydroxy acid dehydratase activity to improve production of fuels, chemicals, and amino acids |
| 8283144, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 8283505, | Dec 27 2007 | Gevo, Inc. | Recovery of higher alcohols from dilute aqueous solutions |
| 8304588, | Dec 27 2007 | Gevo, Inc. | Recovery of higher alcohols from dilute aqueous solutions |
| 8318464, | Oct 04 2007 | CONSORCIO BAL BIOFUELS SA | Biofuel production |
| 8318473, | Oct 04 2007 | CONSORCIO BAL BIOFUELS SA | Biofuel production |
| 8409834, | Jun 18 2010 | GEVO, INC | Extraction solvents derived from oil for alcohol removal in extractive fermentation |
| 8431374, | Oct 31 2007 | GEVO, INC | Methods for the economical production of biofuel from biomass |
| 8455239, | Dec 23 2007 | GEVO, INC | Yeast organism producing isobutanol at a high yield |
| 8476047, | Jun 18 2010 | GEVO, INC | Extraction solvents derived from oil for alcohol removal in extractive fermentation |
| 8557540, | Jun 18 2010 | GEVO, INC | Methods and systems for removing undissolved solids prior to extractive fermentation in the production of butanol |
| 8614077, | Dec 23 2007 | Gevo, Inc. | Recovery of higher alcohols from dilute aqueous solutions |
| 8637281, | Sep 29 2008 | GEVO, INC | Enhanced dihydroxy-acid dehydratase activity in lactic acid bacteria |
| 8637289, | Dec 29 2009 | GEVO, INC | Expression of hexose kinase in recombinant host cells |
| 8669076, | Mar 11 2013 | DUPONT US HOLDING, LLC | Cow rumen xylose isomerases active in yeast cells |
| 8669094, | Jun 05 2008 | GEVO, INC | Enhanced pyruvate to acetolactate conversion in yeast |
| 8735114, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 8759044, | Mar 23 2011 | Butamax Advanced Biofuels LLC; BUTAMAX TM ADVANCED BIOFUELS LLC | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
| 8765425, | Mar 23 2011 | Butamax Advanced Biofuels LLC; E I DU PONT DE NEMOURS AND COMPANY | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
| 8765433, | Dec 29 2009 | GEVO, INC | Alcohol dehydrogenases (ADH) useful for fermentive production of lower alkyl alcohols |
| 8865443, | Jun 18 2010 | GEVO, INC | Extraction solvents derived from oil for alcohol removal in extractive fermentation |
| 8871488, | Jun 18 2010 | GEVO, INC | Recombinant host cells comprising phosphoketolases |
| 8889385, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 8895272, | Oct 31 2007 | Gevo, Inc. | Methods for the economical production of biofuel from biomass |
| 8895307, | Dec 20 2007 | GEVO, INC | Ketol-acid reductoisomerase using NADH |
| 8906656, | Mar 11 2013 | DUPONT US HOLDING, LLC | Cow rumen xylose isomerases active in yeast cells |
| 8911981, | Dec 20 2007 | GEVO, INC | Ketol-acid reductoisomerase using NADH |
| 8945859, | Oct 26 2005 | GEVO, INC | Production of isobutanol by a microorganism with enhanced acetolactate synthase activity |
| 8945899, | Dec 20 2007 | GEVO, INC | Ketol-acid reductoisomerase using NADH |
| 8951774, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 8951937, | Sep 29 2008 | GEVO, INC | Identification and use of bacterial [2Fe-2S] dihydroxy-acid dehydratases |
| 8956850, | Jun 05 2008 | GEVO, INC | Enhanced pyruvate to acetolactate conversion in yeast |
| 8969065, | Jun 05 2008 | GEVO, INC | Enhanced pyruvate to acetolactate conversion in yeast |
| 9068190, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 9109196, | Sep 12 2012 | GEVO, INC | Processes and systems for the production of fermentation products |
| 9169467, | May 11 2012 | GEVO, INC | Ketol-acid reductoisomerase enzymes and methods of use |
| 9181566, | Dec 30 2011 | GEVO, INC | Genetic switches for butanol production |
| 9187743, | Mar 11 2013 | DUPONT US HOLDING, LLC | Bacterial xylose isomerases active in yeast cells |
| 9206443, | Mar 14 2011 | Easel Biotechnologies, LLC | Microbial synthesis of aldehydes and corresponding alcohols |
| 9206447, | Sep 29 2008 | GEVO, INC | Recombinant yeast host cells comprising FE-S cluster proteins |
| 9206448, | Jun 18 2010 | GEVO, INC | Extraction solvents derived from oil for alcohol removal in extractive fermentation |
| 9234217, | Oct 24 2011 | Toyota Jidosha Kabushiki Kaisha | Method for producing isobutanol and recombinant microorganism capable of producing isobutanol |
| 9238801, | Dec 20 2007 | GEVO, INC | Ketol-acid reductoisomerase using NADH |
| 9238828, | Jul 28 2011 | GEVO, INC | Keto-isovalerate decarboxylase enzymes and methods of use thereof |
| 9249076, | Sep 21 2012 | GEVO, INC | Recyclable extractant compositions |
| 9260708, | Sep 29 2009 | GEVO, INC | Yeast production host cells |
| 9267157, | Sep 07 2010 | GEVO, INC | Butanol strain improvement with integration of a polynucleotide encoding a polypeptide that catalyzes pyruvate to acetolactate conversion |
| 9267158, | Mar 14 2013 | PRECIGEN, INC | Biological production of multi-carbon compounds from methane |
| 9273330, | Oct 03 2012 | GEVO, INC | Butanol tolerance in microorganisms |
| 9284612, | Apr 18 2007 | GEVO, INC | Fermentive production of isobutanol using highly active ketol-acid reductoisomerase enzymes |
| 9297016, | Feb 17 2010 | GEVO, INC | Activity of Fe—S cluster requiring proteins |
| 9297029, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 9303225, | Oct 26 2005 | GEVO, INC | Method for the production of isobutanol by recombinant yeast |
| 9365872, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 9371535, | Mar 11 2013 | DUPONT US HOLDING, LLC | Bacterial xylose isomerases active in yeast cells |
| 9371547, | Jun 18 2010 | GEVO, INC | Extraction solvents derived from oil for alcohol removal in extractive fermentation |
| 9388392, | May 11 2012 | GEVO, INC | Ketol-acid reductoisomerase enzymes and methods of use |
| 9399783, | Mar 14 2013 | PRECIGEN, INC | Biological production of multi-carbon compounds from methane |
| 9410166, | Dec 29 2009 | GEVO, INC | Alcohol dehydrogenases (ADH) useful for fermentive production of lower alkyl alcohols |
| 9422581, | Mar 24 2011 | GEVO, INC | Host cells and methods for production of isobutanol |
| 9422582, | Mar 24 2011 | GEVO, INC | Host cells and methods for production of isobutanol |
| 9441250, | Mar 14 2013 | GEVO, INC | Glycerol 3- phosphate dehydrogenase for butanol production |
| 9469584, | Mar 15 2013 | GEVO, INC | Method for producing butanol using extractive fermentation |
| 9469860, | Jan 18 2013 | SYNATA BIO, INC | Method for production of n-butanol from syngas using syntrophic co-cultures of anaerobic microorganisms |
| 9506071, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 9506074, | Feb 12 2010 | Gevo, Inc. | Yeast microorganisms with reduced by-product accumulation for improved production of fuels, chemicals, and amino acids |
| 9512408, | Sep 26 2012 | GEVO, INC | Polypeptides with ketol-acid reductoisomerase activity |
| 9512435, | Feb 17 2010 | GEVO, INC | Activity of Fe—S cluster requiring proteins |
| 9517985, | Mar 15 2013 | GEVO, INC | Method for producing butanol using extractive fermentation |
| 9523104, | Mar 12 2013 | GEVO, INC | Processes and systems for the production of alcohols |
| 9550999, | Jun 18 2010 | GEVO, INC | Recombinant host cells comprising phosphoketolases |
| 9580705, | Mar 15 2013 | GEVO, INC | DHAD variants and methods of screening |
| 9593349, | Aug 22 2012 | GEVO, INC | Fermentative production of alcohols |
| 9605281, | Sep 12 2012 | GEVO, INC | Processes and systems for the fermentative production of alcohols |
| 9611482, | Feb 17 2010 | GEVO, INC | Activity of Fe-S cluster requiring proteins |
| 9650624, | Dec 28 2012 | GEVO, INC | DHAD variants for butanol production |
| 9663759, | Jul 03 2013 | GEVO, INC | Partial adaptation for butanol production |
| 9670511, | Jun 18 2010 | GEVO, INC | Methods and systems for removing undissolved solids prior to extractive fermentation in the production of butanol |
| 9689004, | Mar 23 2012 | GEVO, INC | Acetate supplemention of medium for butanologens |
| 9701992, | Jul 12 2010 | INBIOSE N V | Metabolically engineered organisms for the production of added value bio-products |
| 9708631, | Mar 14 2011 | Easel Biotechnologies, LLC | Microbial synthesis of aldehydes and corresponding alcohols |
| 9738910, | Apr 01 2009 | Process to produce organic compounds from synthesis gases | |
| 9745603, | Mar 14 2013 | PRECIGEN, INC | Biological production of multi-carbon compounds from methane |
| 9765365, | Sep 07 2010 | GEVO, INC | Integration of a polynucleotide encoding a polypeptide that catalyzes pyruvate to acetolactate conversion |
| 9771602, | Mar 15 2013 | GEVO, INC | Competitive growth and/or production advantage for butanologen microorganism |
| 9777297, | Nov 03 2011 | Easel Biotechnologies, LLC | Microbial production of n-butyraldehyde |
| 9790521, | Mar 24 2011 | GEVO, INC | Host cells and methods for production of isobutanol |
| 9840724, | Sep 21 2012 | GEVO, INC | Production of renewable hydrocarbon compositions |
| 9862976, | Oct 26 2005 | GEVO, INC | Fermentive production of four carbon alcohols |
| 9909148, | Dec 30 2011 | GEVO, INC | Fermentative production of alcohols |
| 9909149, | Dec 28 2012 | GEVO, INC | DHAD variants for butanol production |
| 9926577, | Dec 23 2007 | Gevo, Inc. | Yeast organism producing isobutanol at a high yield |
| 9944954, | Mar 14 2013 | GEVO, INC | Glycerol 3-phosphate dehydrogenase for butanol production |
| Patent | Priority | Assignee | Title |
| 4424275, | Sep 17 1979 | BAEOL CORP INC | Continuous process for producing N-butanol employing anaerobic fermentation |
| 4568643, | Sep 17 1979 | Continuous process for producing n-butanol employing anaerobic fermentation | |
| 5210032, | Jan 21 1992 | Trustees of the Boston University | Degeneration-resistant solventogenic clostridia |
| 6358717, | May 13 1998 | ILLINOIS, UNIVERSITY OF THE BOARD OF TRUSTEES, THE | Method of producing butanol using a mutant strain of Clostridium beijerinckii |
| 20020028492, | |||
| CA2039245, | |||
| EP112459, | |||
| EP282474, | |||
| EP315949, | |||
| EP1149918, | |||
| JP61209594, | |||
| JP63102687, | |||
| JP6317695, | |||
| JP63254986, | |||
| WO50624, | |||
| WO121772, | |||
| WO2008072920, | |||
| WO2008072921, | |||
| WO9002193, | |||
| WO9851813, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 25 2006 | Butamax(TM) Advanced Biofuels LLC | (assignment on the face of the patent) | / | |||
| Nov 30 2006 | DONALDSON, GAIL K | E I DU PONT DE NEMOURS AND COMPANY | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018653 | /0165 | |
| Nov 30 2006 | MAGGIO-HALL, LORI ANN | E I DU PONT DE NEMOURS AND COMPANY | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018653 | /0165 | |
| Nov 30 2006 | ELIOT, ANDREW C | E I DU PONT DE NEMOURS AND COMPANY | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018653 | /0165 | |
| Nov 30 2006 | FLINT, DENNIS | E I DU PONT DE NEMOURS AND COMPANY | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018653 | /0165 | |
| Dec 03 2006 | NAGARAJAN, VASANTHA | E I DU PONT DE NEMOURS AND COMPANY | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 018653 | /0165 | |
| Mar 31 2010 | E I DU PONT DE NEMOURS AND COMPANY | Butamax Advanced Biofuels LLC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024216 | /0243 | |
| Sep 21 2021 | Butamax Advanced Biofuels LLC | GEVO, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 057677 | /0477 |
| Date | Maintenance Fee Events |
| May 14 2014 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| May 14 2014 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| May 31 2018 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| May 31 2018 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Jun 09 2022 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Jun 09 2022 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Jun 13 2023 | SMAL: Entity status set to Small. |
| Date | Maintenance Schedule |
| Dec 14 2013 | 4 years fee payment window open |
| Jun 14 2014 | 6 months grace period start (w surcharge) |
| Dec 14 2014 | patent expiry (for year 4) |
| Dec 14 2016 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 14 2017 | 8 years fee payment window open |
| Jun 14 2018 | 6 months grace period start (w surcharge) |
| Dec 14 2018 | patent expiry (for year 8) |
| Dec 14 2020 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 14 2021 | 12 years fee payment window open |
| Jun 14 2022 | 6 months grace period start (w surcharge) |
| Dec 14 2022 | patent expiry (for year 12) |
| Dec 14 2024 | 2 years to revive unintentionally abandoned end. (for year 12) |